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Thirty percent of pediatric epilepsies become resistant to conventional treatments, 
such as antiepileptic drugs and ketogenic diets.  Growing anecdotal evidence of using 
Cannabis for treating epilepsy has prompted parents to acquire Cannabis products for their 
children without the consent or guidance of their pediatrician. Limited scientific based 
evidence exists for pediatric epilepsy and Cannabis therapy. Establishing a standard 
dosage regimen to ensure the safety and efficacy with Cannabis based medicine for 
pediatric epilepsy requires conducting a pharmacokinetic (PK) study to define the age-
dependent pharmacokinetic parameters. 
 The Cannabidiol and Children with Refractory Epileptic Encephalopathy (CARE-E) 
open-labelled dose escalation study utilizing a 1:20  D9-tetrahydrocannabinol (THC): 
cannabidiol (CBD) Cannabis herbal extract containing 4% cannabichromene (CBC) will 
establish a recommended dose for the PK study and define the relationship between the 
minimum cannabinoid plasma concentration at steady state (Css,min) and dose. A sensitive 
and selective liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was 
utilized to quantify the Css,min. Participant A-04 exhibited a greater than proportional increase 
in Css,min relative to the dose (10-12 mg/kg/day), indicating non-linear PK. No THC 
intoxication was observed during the study. All participants displayed linear 
pharmacokinetics and seizure frequency reductions at 5-6 mg/kg/day, recommending the 5-
6 mg/kg/day dose to be used for the PK study.  
 Ketogenic diets, a high fat diet used for pediatric epilepsy, may alter the plasma 
levels of lipoproteins, a major plasma protein in cannabinoid plasma protein binding. The 
unbound cannabinoid concentration is only able to produce a pharmacological effect; 
therefore, it is imperative to determine the effects ketogenic diets impart on protein binding 
to conclude if dosage adjustments are necessary. Cannabinoids may exhibit non-specific 
binding or buffer solubility issues observed with the commonly used plasma protein binding 
assays. A novel 3-extraction technique was developed for lipophilic compounds to avoid 
these issues. A comparative analysis was conducted between commonly used techniques 
(ultrafiltration and rapid equilibrium dialysis) and the 3-solvent extraction technique, with the 
3-solvent extraction technique providing higher cannabinoid recovery and assay 
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reproducibility, indicating 82.7%, 82.1%, 87.0%, and 93.4% plasma protein binding of 11-
OH-THC, CBD, THC, and CBC, respectively.  
 With legalization of recreational Cannabis, there has been growing concern over 
pregnant women consuming Cannabis. Cannabinoids can cross the blood placental barrier 
and reach the fetal systemic circulation. Increased Cannabis use during pregnancy would 
be a public health concern; therefore, it is crucial to determine the prevalence of prenatal 
Cannabis exposure. This was determined using residual neonate dried blood spot (DBS) 
screening cards collected from April, May, and June 2018 (pre-legalization) and April, May, 
and June 2019 (post-legalization). Due to its long half-life 11-nor-9- carboxy- D9-
tetrahydrocannabinol (THC-COOH), an inactive THC metabolite, is a suitable drug marker 
for Cannabis exposure. A quantitative LC-MS/MS assay was initially developed, however, 
factors such as hematocrit effect, chromatographic effect, and sample heterogeneity 
contributed to inaccurate and imprecise cannabinoid quantification. Alternatively, a 
qualitative LC-MS/MS assay, which solely utilizes a limit of detection (LOD), was applied, 
establishing a LOD of 1.47 ng/mL. Currently, we detected THC-COOH in 11 of 220 
Saskatchewan residual neonate DBS cards collected pre-legalization, indicating a 5% 
prenatal Cannabis exposure rate.  
 The recommended dose obtained from the CARE-E dose escalation study and the 
LC-MS/MS assay will be utilized in single oral dose pharmacokinetic studies in the pediatric 
population to characterize the required age dependent pharmacokinetic parameters for 
establishing a standard dosage regimen. The 3-solvent extraction technique will determine 
the influence ketogenic diets have on the cannabinoid plasma protein binding profile and if 
dosage adjustments are necessary. Complete analysis of the pre- and post-legalization 
Saskatchewan, Manitoba, and British Columbia residual neonate dried blood spot samples 
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1 Introduction  
 
Cannabis sativa has gained interest as potential treatment for multiple medical 
conditions, including cancer, HIV, epilepsy, diabetes, among other disorders. The 
pharmacology of plant-derived cannabinoids, also known as phytocannabinoids, 
presents large knowledge gaps. The determination of the therapeutic properties of 
Cannabis and cannabinoids, specifically cannabidiol, requires further, extensive 
research. Recently, Cannabis-based medicines (CBM) have gained more attention as 
an alternative treatment for children with refractory epileptic encephalopathy. Still, 
doctors hesitantly consider giving their pediatric patients CBM, due to current lack of 
knowledge on the safety and efficacy of Cannabis treatment. However, anecdotal 
reports of antiepileptic properties of CBM have motivated some parents to acquire 
Cannabis products from unregulated distributors and without the knowledge of their 
doctor.  
Parents expose Cannabis to their children without clear knowledge of the safety 
and efficacy of Cannabis. In a therapeutic context, this practice can be harmful as no 
standard dose of Cannabis currently exists for children. To be detailed, a high dose can 
lead to a child overexposed to Cannabis, resulting in unwanted, adverse effects, while a 
low dose can lead to underexposure, which may result in a child reaching 
subtherapeutic levels. Exposure to high D9-tetrahydrocannabinol (THC) and cannabidiol 
(CBD) concentrations may not benefit children, potentially putting them at risk. The 
ability to quantify phytocannabinoids, and their metabolites in biological matrices is a 
first step to understanding the safety and efficacy of Cannabis exposures in children.  
The objectives of my thesis include 1) developing liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) methods for quantifying CBD, THC, 11-OH-THC, and 
CBC in human plasma and dried blood spots; 2) applying the developed LC-MS/MS 
method to measure minimum steady state plasma cannabinoid concentrations (Css,min) 
in pediatric patients with refractory epileptic encephalopathy on Cannabis oil therapy in 
the Cannabidiol and Children with Refractory Epileptic Encephalopathy (CARE-E) 
study; 3) determining the plasma protein binding profiles of cannabinoids in human 
plasma; and 4) applying the LC-MS/MS method to determine the prevalence of prenatal 
 2 
Cannabis exposure pre- and post-legalization of recreational Cannabis using residual 
newborn screen cards. Of note, the CARE-E study is designed to assess the safety and 
tolerability of CBM in children as well as provide an appropriate starting dose for future 
pharmacokinetic (PK) studies in the pediatric population.  
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2 Literature Review 
 
2.1 Refractory Epileptic Encephalopathy 
 
2.1.1 What is refractory epileptic encephalopathy? 
 
Refractory epileptic encephalopathy is an aggressive group of epilepsy disorders 
with seizures that can lead to neurological impairments, such as cognitive and 
psychoactive disorders, and behavioral issues.1 It was recently reported that 6.9 of 1000 
children in Canada are diagnosed with epilepsy.2 Of these children, 30% develop 
epilepsies that are treatment resistant. Epilepsy occurs due to the irregular electrical 
discharges from different regions of the brain.3 Many types of epileptic disorders fall into 
the category of pediatric refractory epileptic encephalopathy, including Lennox-Gastaut 
syndrome (LGS), Dravet syndrome, infantile spasms, and continuous spike wave sleep 
(CSWS/ESES). 
Lennox-Gastaut syndrome, a rare form of epilepsy, represents 1-10% of 
childhood epilepsies, usually occurring in children before the age of 8, most commonly 
during the ages of 3 and 5 years old.4 Types of seizures associated with LGS include 
tonic and atypical absence seizures (seizures that start slow with mild impairment of 
consciousness), myoclonic (brief jerks of the muscle), generalized tonic-clonic (seizure 
that affects the whole brain, causing individual to lose consciousness while muscles 
stiffen and spasm), and focal seizures (affects a region of the brain and the individual 
can either be conscious or unconscious while seizures occur).4  LGS can lead to lesions 
in varying brain regions, potentially resulting in prominent cognitive and social 
impairments.4,5  
Dravet syndrome, another rare but severe form of epilepsy, affects 1 in 15,700 
people in the United States.6 Types of seizures associated with Dravet syndrome 
include clonic/hemiclonic convulsive seizures (uncontrolled jerking), myoclonic seizures, 
focal seizures, and absence seizures.7 The disruptive paroxysmal 
electroencephalogram (EEG) pattern consists of quick, short or isolated spike waves 
induced by eye closure.8 Dravet syndrome results in central nervous system effects 
such as frequent seizures, developmental delays, speech impairment, and motor 
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issues.6 Individuals with Dravet syndrome have increased risk of sudden unexpected 
death in epilepsy (SUDEP).6 
The prevalence of infantile spasms occurs in 1-4 out of 10000 births. Infantile 
spasms usually appear at the early stage of childhood; most commonly occurring from 
3-5 months of age.9 These types of seizures occur during the stages of waking up or the 
early stages of sleep.9 Infantile spasms develop disorganized EEG patterns, called 
hypsarrthythmia, consisting of a cluster of high voltage slow wave spikes followed by 
attenuation of paroxysmal fast activity.10 Some individuals eventually recover from 
infantile spasms, but most often individuals remain with cognitive impairments 
throughout their whole life.10  
Continuous spike wave sleep (CSWS), also known as electrical status epilepticus 
in sleep, has a prevalence of 0.5-0.6% in all childhood epilepsies.11 This rare form of 
epilepsy consists of epileptic discharges during the slow sleep cycle, with an EEG 
pattern of constant spikes and waves. However, this pattern stops during the REM 
cycle.12 After onset of CSWS, neurocognitive deterioration begins, affecting motor, 
behavioral, and language development.11 This form of epilepsy does not result in the 
formation of lesions.  
 
2.1.2 Treatments of Epilepsy 
 
Many different antiepileptic drugs (AEDs) are available for treatment of epilepsy. 
Some of the common AEDs prescribed include clobazam, stiripental, topiramate, 
lamotrigine, levetiracetam, phenytoin, carbamazepine, valproic acid, and clonazepam. 
Individuals may be prescribed a single AED, or multiple AEDs, depending on the degree 
of their epileptic disorders. Some AEDs have a narrow therapeutic index, meaning slight 
changes in dose or blood concentration can elicit toxic effects.13 This can be harmful, 
with potential for relapse of seizures or other negative side effects.13 Often, antiepileptic 
drugs are ineffective against refractory epileptic encephalopathy.14 Patients can develop 
tolerance or resistance to the effects of AEDs.  
One possible cause of epileptic encephalopathy results from a metabolic disorder 
associated with glucose transporter 1 deficiency. The movement of glucose across the 
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blood brain barrier requires the functionality of glucose transporter 1 (GLUT-1).15 Any 
deficiency in GLUT-1 function will result in reductions in glucose levels in the brain, the 
main biochemical energy source. To compensate for decreased brain glucose levels, 
epileptic children with a GLUT-1 deficiency may undergo a ketogenic diet, a diet 
consisting of foods with high fat content. Although firstly introduced in the 1920s, the 
ketogenic diet did not gain interest as a form of epileptic treatment until the 1990s.16 
Although the true mechanism of the ketogenic diet remains unknown, ketone 
bodies may act to replace glucose as the new energy source for the brain.15 Fatty acids 
can produce ketone bodies through ketogenesis. Enzymatically, fatty acids from dietary 
lipids undergo b-oxidation to produce acetyl-CoA, which in turn forms ketone bodies 
acetoacetate and b-hydroxybutyrate. Due to low carbohydrate levels in the diet, the 
body reduces its glucose utilization and switches to ketone bodies, produced from fatty 
acids.1517 The ketone bodies act as the main source for energy production through 
cellular metabolism, helping to regulate neuronal function.16 
Children with epilepsy typically use four types of ketogenic diets – classic 
ketogenic diet (KD), medium-chain triglyceride ketogenic diet (MCT), modified Atkins 
diet (MAD), and low glycemic index treatment (LGIT).18 Classic ketogenic diet consists 
of excluding carbohydrates while increasing the intake of high-fat foods. Medium-chain 
triglyceride ketogenic diets contain more ketone bodies per unit of energy in comparison 
to the other ketogenic diets, which consists of long-chain triglycerides.18 MCT diets have 
less restrictions than the classic ketogenic diet, meaning lower levels of fat intake and 
more allowance for carbohydrate intake.19 This makes the less restrictive ketogenic diet 
more appealing and nutritional. The modified Atkins diet consists of a ratio of 1-gram fat 
to 1 gram of carbohydrates and proteins combined.20 Lastly, the low glycemic index 
treatment focuses on restricting the intake of carbohydrates, only allowing the 
consumption of foods with a glycemic index of 40-60 grams per day.20  
Many children discontinue the diet due to the inadequate nutritional value and the 
strict guidelines of the diet, as well as side effects that can occur while on the diet.18 The 
side effects include high cholesterol levels, constipation, gastroesophageal reflux, 
vitamin D deficiency, kidney stones, and osteomalacia.21 Due to the strict ketogenic diet, 
children may not receive proper nutrition needed for healthy growth, which can lead to 
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other health effects. If children decide to pursue a ketogenic diet, vitamin 





2.2.1 Endocannabinoid system 
  
The endocannabinoid system consists of cannabinoid receptors, 
endocannabinoids, and enzymes that play a role in the chemical and biological 
processes associated with endocannabinoids.22 Cannabinoid receptors, located in the 
central and peripheral nervous system, consists of two main cannabinoid receptors- 
cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2). CB1 receptors, predominantly 
found in the central nervous system, modulate neurotransmission.23  CB1 receptors 
located on the presynaptic terminals of GABAergic and glutamatergic neurons, affect 
the release of γ-amino butyric acid (GABA) and glutamate neurotransmitters in the 
human body.22,23 CB1 receptors also regulate opioids, dopamine and serotonin.24 
Cannabinoid type 2 receptors, predominantly found in immune cells (such as T cells, B 
cells, and monocytes), modulate the immune response.23 
Cannabinoid receptors mainly associate with Gi/Go proteins, inhibiting adenylyl 
cyclase and activating mitogen-activated protein kinase (MAP kinase).22 Adenylyl 
cyclase catalyzes adenosine triphosphate (ATP) into 3’,5’-cyclic adenosine 
monophosphate (cAMP), a second messenger necessary for the stimulation of protein 
kinase A.25 Activation of CB1 receptors also causes the inhibition of voltage-gated 
calcium (Ca2+) channels and activation of inwardly rectifying potassium (K+) channels. 
Their activation results in the extension of the resting membrane potential, which can 
reduce the length of action potentials.22 Inhibition of voltage-gated Ca2+ channels can 
prevent the formation of neurotransmitter vesicles, inhibiting neurotransmitter release.  
Depending on the type of neurons as well as the brain region expressing CB1 
receptors, different effects can occur. Activation of CB1 receptors on glutaminergic 
neurons inhibit glutamate, an excitatory neurotransmitter, leading to a reduction in 
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neuronal excitation. Inhibition of glutamate release in the hippocampus, basal ganglia, 
and midbrain will affect memory, movement coordination, and pain response, 
respectively.26 Activation of CB1 receptors on GABAergic neurons will inhibit GABA, an 
inhibitory neurotransmitter, leading to an increase in neuronal excitation.  The 
mechanism of the inhibition of GABA remains unknown, as many speculate this process 
would have counteracted the effects of glutamate inhibition, but this is not the case.26 
Cannabinoid receptors are not just exclusive to cannabinoid type 1 and 2 (CB1 and CB2 
receptors), but they include orphan cannabinoid receptors, such as GPR18, GPR55, 
and vanilloid type receptors.27  
Endocannabinoids originate endogenously in the body and are fatty acid 
cannabinoids derived from arachidonic acid-containing phospholipids. The two main 
endocannabinoids are arachidonoylglycerol (2-AG) and anandamide (AEA or 
arachidonoylethanolamide) (Figure 2.1).28 Raphael Mechoulam identified the first 
endocannabinoid, AEA, a partial agonist of CB1 receptors .28 Both 2-AG, a full agonist of 
CB1 receptors, and AEA have an “on demand” synthesis and release, meaning neuron 
induction must occur for synthesis of endocannabinoids. AEA and 2-AG depend on the 
release of Ca2+.29 In the presence of a phospholipase D-like enzyme, N-arachidonoyl-
phosphatidyl-ethanolamine hydrolyzes to produce AEA. sn-2-Arachidonate-containing 
diacylglycerol depends on sn-1-diacylglycerol lipase for the formation of 2-AG.29 These 
ligands play an important role in physiological processes, such as emotions, appetite, 
and pain sensitivity.30 When activating CB1 receptors, anandamide can also lower blood 
pressure, leading to bradycardia.29 Cannabinoid receptor activation requires small 
amounts of 2-AG production.29 Termination of endocannabinoid activity follows after the 
release from the cannabinoid receptors, transporting into the neurons where they 
undergo degradation.29  
An understanding of how endocannabinoids cross the plasma membrane remains 
unknown; however, studies have suggested that AEA and 2-AG undergo passive 
diffusion or endocytosis before undergoing intracellular transport for inactivation.31  
Once in the neuron, endocannabinoids require the presence of a carrier protein to 
mediate transport within the cell.29 Fatty acid-binding proteins (FABPs) as well as heat 
shock proteins 70.2 (HSP70.2) act as intracellular carriers for AEA and 2-AG, 
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solubilizing and transporting them to fatty acid amide hydrolase (FAAH) or 
monoacylglycerol (MAGL) to be inactivated.32 FAAH can degrade both AEA and 2-AG, 
forming arachidonic acid and ethanolamine (from AEA) as well as glycerol (from 2-
AG).29 MAGL selectively degrades 2-AG, forming arachidonic acid and glycerol.29  
The presence of the phytocannabinoids, THC and CBD, can increase the levels of 
AEA and 2-AG by binding to FABPs, resulting in inhibition of FABPs.32 Because FABPs 
are inhibited, AEA and 2-AG cannot be transferred to FAAH to be inactivated, resulting 
in an accumulation of circulating endocannabinoids.32  The accumulation of AEA and 2-
AG will prolong the effects associated with the endocannabinoids. 
 
2.2.2 Cannabinoids  
 
Cannabinoids are a class of chemical compounds that share similar structural 
and/or functional properties of Δ9-tetrahydrocannabinol (THC) that act on cannabinoid 
receptors. Cannabinoids categorize into three classes: phytocannabinoids, 
endocannabinoids, and synthetic cannabinoids. The phytocannabinoids originate from 
the Cannabis sativa plant. To date, researchers have identified 565 compounds in the 
Cannabis plant, including more than 120 cannabinoids. Of these 120 compounds, some 
of the most discussed phytocannabinoids involve Δ9-tetrahydrocannabinol (THC), 
cannabidiol (CBD), 11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-THC), 11-nor-9-
carboxy-Δ9-tetrahydrocannabinol (THC-COOH), cannabinol (CBN), and 




Figure 2.1. Chemical structures of phytocannabinoids, endocannabinoids, and synthetic cannabinoids- a) 
cannabidiol, b) D9-tetrahydrocannabinol, c) 11-hydroxy-D9-tetrahydrocannabinol, d) 11-nor-9-carboxy-D9-
tetrahydrocannabinol, e) cannabinol, f) cannabichromene, g) 6-a-hydroxy-cannabidiol, h) 6-b-hydroxy-
cannabidiol, i) 7-hydroxy-cannabidiol, j) anandamide, k) 2-arachidonoylglycerol, l) HU-210, m) WIN 55, 






Although discovered in the 1930s, the isolation of THC, the main psychoactive 
cannabinoid of Cannabis sativa, did not occur until 1964.33 Tetrahydrocannabinolic acid 
(THCA), the precursor of THC and primary form found in the Cannabis plant, undergoes 
decarboxylation via light or heat, to produce THC. After consumption, THC rapidly 
metabolizes to 11-OH-THC, its main secondary psychoactive metabolite.32 11-OH-THC 
further metabolizes to THC-COOH, a non-psychoactive metabolite of THC. Forensic 
labs often use 11-OH-THC to determine recent Cannabis exposure. THC-COOH is a 
biomarker used in clinical and forensic labs to detect exposure to Cannabis. THC-
COOH undergoes conjugation to produce THC-COOH-glucuronide, a major water-
soluble urinary metabolite of THC. The high concentration of CB1 receptors found in the 
central nervous system is responsible for the psychoactive effects, observed mostly in 
THC, a partial agonist the receptor.34,35 Researcher assume the psychoactive properties 
associated with THC stems from the high concentration of CB1 receptors found in the 
central nervous system.35 
Cannabidiol (CBD) is one of the main therapeutic cannabinoids found in Cannabis 
sativa. Although considered a non-psychoactive cannabinoid, CBD exerts antianxiety 
and other neurological effects.36 Similarly to THCA, the precursor cannabidiolic acid 
(CBDA) undergoes decarboxylation to produce CBD. The mechanism of cannabidiol 
(CBD) still remains unclear as CBD has a low affinity for both CB1 and CB2 receptors, 
although CBD has a greater affinity to CB2 receptors compared to CB1 receptors, which 
may explain the absence of psychoactive properties in CBD.35  
It is assumed that CBD binds to various non-cannabinoid receptors, such as 
GPR55 receptors, TRPV1 receptors, 5-HT1A receptors, and more recently discovered 
GPR3 and GPR6 receptors.37,38 It is believed that CBD binds to TRPV1 receptors, 
eliciting anti-inflammatory and antinociceptive effects by desensitizing nociceptors.39 
Additionally, CBD binds to 5-HT1A receptors, serotonin receptors that modulate anxiety, 
mood, and hunger. Binding of CBD to these receptors may display protective effects 
against ischemia (inadequate blood supply to the heart) and also produces anxiolytic 
effects, which reduces anxiety.39 
Synthetic cannabinoids, man-made chemical compounds, have the same 
psychoactive effects observed in phytocannabinoids. They are used commonly because 
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they are not considered to be a controlled substance.40 The consumption of synthetic 
cannabinoids has been declining in the United States due to the legalization of medical 
and recreational Cannabis. Common synthetic cannabinoid drug brands found in the 
market include Spice and K2. These drugs are marketed as herbal blends, directed for 
the usage as incense.41 Included in these drugs are synthetic cannabinoids WIN 55, 
212-2, HU210, and JWH-018 (Figure 2.1). Studies have shown that HU210, a CB1 and 
CB2 receptor agonist, may reduce gastric acid and pepsin secretion, as well as reduce 
inflammation in acute pancreatitis.42 JWH-018, an agonist of both CB1 and CB2 
receptors, has greater affinity to the cannabinoid receptors, compared to THC. Higher 
affinity to the CB receptors explains the adverse side effects of JWH-018, such as 
vomiting, headaches, paranoia, tachycardia, seizures, and hallucinations.43  
While effects may be similar to some phytocannabinoids, synthetic cannabinoids 
tend to reach their peak effects more rapidly.44 Issues exist with these synthetic 
cannabinoid drugs as they are usually laced with other components that are not stated 
on the label. In fact, some ingredients do not match what is listed in the mixture, causing 
uncertainty in the degree of potency and safety of the product.41  
 
2.2.3 Therapeutic use of Cannabis 
 
Since ancient times Cannabis has been used therapeutically for many different 
health conditions, including chronic pain, nausea/vomiting resulting from chemotherapy, 
diabetes, anxiety, depression, epilepsy, cachexia resulting from HIV/AIDS and cancer, 
and other conditions.45 The use of Cannabis for the diverse range of health issues in 
part relates to the different physiochemical characteristics displayed by many distinctive 
phytocannabinoids present in the plant Cannabis sativa.  
Two synthetic THC analogs are currently the only Food and Drug Administration 
(FDA) approved cannabinoid drug in the United States – Dronabinol (also known as 
Marinol) and Nabilone. Both Dronabinol and Nabilone are given to patients dealing with 
nausea and vomiting associated with chemotherapy, and Dronabinol also is used for 
anorexia and wasting seen in Human Immunodeficiency Virus (HIV) patients.45 
Dronabinol is no longer available in Canada due to its psychoactive effects. Another 
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cannabinoid drug is Nabiximols, an oral spray containing a mixture of CBD and THC. 
Nabiximols is approved in Canada for the use in treatment-refractory cancer pain, 
multiple sclerosis spasms, and central pain.45  
 
2.2.4 Side effects of Cannabis use 
 
The therapeutic use of Cannabis is associated with some important 
consequences. With the benefits come the side effects, some considered severe and 
permanently damaging, especially in children. While THC helps relieve the symptoms of 
spinal cord injury, Parkinson’s disease, cachexia, and Crohn’s disease, the 
psychoactive effects tend to deter patients from medical Cannabis. These psychoactive 
effects can include anxiety, dysphoria, memory impairment, and psychomotor and 
cognitive performance impairment.33 Additionally, the brain does not reach full 
maturation until the age of 25. Considering the central nervous system contains CB1 
receptors, long duration of exposure to high THC concentrations may cause long-term 
detrimental effects.46   
Although CBD has fewer side effects compared to THC, if taken in high doses, 
CBD can alter cytochrome P450 (enzymes found in the liver) activity, thus changing 
hepatic drug metabolism.35 High CBD doses can also increase tremors associated with 
Parkinson’s disease. Lowering the dose may relieve these side effects but lowering the 
dose may result in subtherapeutic levels.35 High CBD doses may temporarily cause 
immediate low blood pressure followed by lightheadedness.35 
 
2.2.5 Prenatal Cannabis exposure 
  
Legalization of recreational Cannabis use raises concerns of women consuming 
Cannabis during pregnancy. In Spain, detection of cannabinoids in the meconium 
determined a prevalence of Cannabis exposure of 5.3%, comparable to the international 
prevalence of 4.5%, with Cannabis reported as the most used illicit drug by pregnant 
women in Western countries.47 Other surveys have reported prevalence of prenatal 
Cannabis exposure between 5-16%.48 A study conducted in Ontario, Canada reported 
an increase prevalence of prenatal Cannabis exposure from 1.2% in 2012 to 1.8% in 
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2017.49 Expectedly, this number will increase with more accessibility after the 
legalization of recreational Cannabis.  
Varying numbers reported stem from the challenges in self-reporting pregnant 
women. These challenges include under-reporting, risk of legal consequences, and 
possible loss of child custody.47 Cannabis is now considered the number one drug of 
abuse in pregnant women. Pregnant women perceive Cannabis less harmful to the 
fetus compared to other drugs, such as cocaine, heroin, and methamphetamine.48 
Synthetic cannabinoids are more potent than phytocannabinoids, due to high affinity for 
the CB receptors.48  
A study in Colorado reported 69% of the Cannabis retailers surveyed promoted 
the use of Cannabis to treat morning sickness, while 36% deemed Cannabis use safe 
during pregnancy.50 Majority of women while pregnant report using Cannabis to help 
relieve the nausea and vomiting associated with morning sickness, with no 
understanding of the damage that can be done to the fetus.50 With legalization, 
pregnant women have more access to obtain recreational Cannabis without their 
physician’s consent. Many women do not know they are pregnant while consuming 
Cannabis products while some women are unaware about the consequences of using 
Cannabis while pregnant.  
The endocannabinoid system plays a significant role in reproduction. The ECS 
contributes to fertilization, oocyte transport, implantation, embryo development, and 
immune regulation.51,52 Studies suggest a decrease in FAAH enzymes, which 
metabolizes endocannabinoid AEA, is linked to spontaneous miscarriages.52 During 
embryo development, AEA is highly controlled. High AEA levels during the non-
receptive stage and low AEA level during the receptive stage of implantation suggests 
AEA downregulation important for successful embryo implantation.52 Exposure to THC 
can increase AEA levels by inhibiting FABP, potentially leading to unsuccessful 
fertility.48  
The uterine endometrium, placenta, and ovaries express cannabinoid receptors. 
Cannabinoid receptors start developing around 14 weeks of gestation and increase 
during the third trimester, with the greatest density located in the frontal lobe and 
cerebellum.47 One-third of cannabinoids present in the maternal plasma crosses the 
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placental barrier.47 In vitro exposure of CBD to placental cells inhibited breast cancer 
resistance protein (BCRP) and p-glycoprotein (P-gp) efflux transport, enhancing the 
permeability of other cannabinoids and xenobiotics.48,53 
In rats, prenatal Cannabis exposure resulted in changes to the dopaminergic 
activity in the corpus striatum, a section of the brain responsible for motor and reward 
activity.46,53 Reduced dopamine levels links to increase risk of attention deficit 
hyperactivity disorder (ADHD) and changes in motor activity. Reduced dopamine levels 
in the prefrontal cortex and hypothalamus-pituitary axis also make the neonate 
susceptible to cognitive impairment and emotional dysregulation.47,48  
There is still a lack of understanding on the effects of Cannabis exposure during 
the early or late stages of pregnancy. One study suggests Cannabis use early in 
pregnancy increases the risk of physical development, such as inadequate fetal growth, 
lower birth weight, small head circumference, and thicker prefrontal cortex.47,54 
Cannabinoids can decrease the subpopulation of T cells, leading to potential immune 
dysregulation, an effect prominent throughout adolescence and adulthood.48 Increased 
anxiety and depression due to prenatal Cannabis exposure is exhibited as early as 
childhood through adulthood.47,48 Many effects are not immediately detected and can 
take years before any neurodevelopmental impairments are displayed. In school age 
children, those exposed to Cannabis prenatally had delayed development with speech 
and language skills.48  
With the increase of Cannabis accessibility after the legalization of recreational 
Cannabis, more research is needed to determine the long-term effects Cannabis use 
has on the fetus. 
 
2.2.6 Therapeutic Cannabis use in pediatric population  
 
 Incidence of pediatric and adolescent Cannabis exposure has increased with the 
decriminalization of recreational and medical Cannabis use. This increase allowed for 
greater accessibility of regulated Cannabis products for pediatric therapeutic use 
without the knowledge or guidance of a pediatrician. Cannabis based medicine (CBM) 
has gained interest for its use in treatment resistant disorders, including pediatric 
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epilepsy. Considerable evidence of successful Cannabis use for pediatric treatment 
exist; however, most are anecdotally based rather than scientifically based. Therapeutic 
use of Cannabis for the pediatric population includes autism, perinatal brain injury, 
neuroblastoma, chemotherapy-induced nausea and vomiting (CINV), neuropathic pain, 
post-traumatic stress disorder (PTSD), Tourette syndrome, major depressive disorder, 
and epilepsy.55,56  
Cannabis use for pediatric treatment focuses mainly on treatment of pediatric 
epilepsy. The ECS has shown to play an important role in the mechanism in seizures. 
During a seizure episode, the excessive glutamate release will cause CB1 receptors to 
provide a negative feedback mechanism by reducing glutamate release, ultimately 
reducing neuronal hyperexcitability.57 However, individuals with epilepsy appear to have 
downregulation of CB1 receptors on glutaminergic axon terminals and upregulation on 
GABAergic axon terminals, creating an imbalance in the ECS which can contribute to 
epileptic activities.57  
Few studies have investigated the efficacy of purified CBD oil for pediatric 
epilepsy. Devinsky et al. conducted a 12-week open label clinical trial using Epidiolex in 
162 participants with doses titrated up to a maximum of 25 mg CBD/kg/day, 
administered twice daily.58 Studies using purified CBD oil report administration of higher 
CBD doses, averaging around 20-25 mg/kg/day. Devinsky reported a median of 36.5% 
reduction in seizure frequency at 25 mg/kg/day. Additionally, in 2017, Devinsky et al. 
conducted a 14-week randomized clinical trial using Epidiolex, with a dose of 20 mg 
CBD/kg/day in 120 participants.59 Participants receiving CBD treatment reported a 
median of 38.9% seizure frequency reduction. Thiele et al. also conducted a 
randomized clinical trial using purified CBD oil at a similar dose of 20 mg CBD/kg/day, 
reporting a median of 43.9% reduction in seizure frequency.60 However, participants 
receiving the placebo reported a 21.8% reduction in seizures, making it difficult to 
understand the true CBD efficacy.  
The entourage effects between cannabinoids and terpenes in CBM may provide 
similar effects of purified CBD but at lower doses. Terpenes, such as linalool, potentially 
display anticonvulsant properties by modulating neuronal excitability, specifically 
decreasing glutamate release.61 A 20-week open label trial led by McCoy et al. 
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determined the efficacy of a 1:50 THC:CBD CBM in 20 participants, using a dose of 16 
mg CBD/kg/day administered twice daily.62 The median seizure frequency reduction 
was reported at 70.6%.  Tzadok et al. conducted a retrospective study with 1:20 
THC:CBD CBM, with doses ranging from 1-20 mg CBD/kg/day, with majority of 
participants administered <10 mg CBD/kg/day.63 89% of participants reported a 
reduction in seizures, with 52% obtaining >50% seizure frequency reduction.  Hausman-
Kedem et al. conducted an observational, longitudinal study to determine efficacy of a 
1:20 THC:CBD CBM in 69 participants.64 Initial maximum dose was set to 50 mg 
CBD/kg/day administered three times daily. However, participants could only tolerate 
doses of 4-32 mg CBD/kg/day, with an average of 11.4 mg CBD/kg/day. 56% of 
participants achieved >50% seizure reduction frequency.  
While research on Cannabis use for the pediatric population has steadily 
increased, large gaps of knowledge still exist, such as the safety and efficacy. Published 
clinical studies provide large disparities with the use of pure CBD or cannabinoid herbal 
extracts, amounts of CBD and THC in CBM, and dose. Purified CBD oils are less 
accessible due to higher costs and regulatory restrictions.65 Purified CBD oils do not 
contain any THC, avoiding any possible psychoactive effects associated with THC 
consumption. Practitioners are hesitant to prescribe CBM due to possible THC 
intoxications. Most CBMs contain low amounts of THC, reducing the adverse side 
effects associated with the psychoactive cannabinoid. Standardization of the dose and 
type of CBM is necessary to ensure appropriate safety and efficacy.   
 
2.2.7 Safety concerns with Cannabis use in the pediatric population 
 
A majority of participants in clinical trials experienced at least one form of 
adverse effects. Most adverse effects associated with therapeutic use of CBD are mild 
to moderate, including somnolence, fatigue, vomiting, nausea, and decrease in 
appetite.58-64 Severe, but rare, adverse effects include status epilepticus, diarrhea, 
pneumonia, increase levels of liver aminotransferase enzymes, and weight loss. The 
most common adverse effect, somnolence, was associated with participants taking 
clobazam and CBM concomitantly.  
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Use of Cannabis based medicine as an adjuvant treatment to AEDs can lead to 
drug-drug interactions. As a CYP2C19 inhibitor, CBD increases N-desmethylclobazam, 
an active metabolite of clobazam, potentially causing overexposure to clobazam.65,66 
The majority of adverse effects decreased with dose reduction of CBM or dose 
adjustment/removal of AEDs. 
 
2.2.8 CARE-E study 
 
The Cannabidiol in Children with Refractory Epileptic Encephalopathy (CARE-E) 
study, led by Dr. Richard Huntsman, a pediatric neurologist from University of 
Saskatchewan, and Richard Tang-Wai, a pediatric neurologist from University of Loma 
Linda, investigated the use of CBM to treat pediatric epilepsies nonresponsive to 
anticonvulsant drugs and ketogenic diet.67 The study used purified Cannimed herbal 
extract with a 1:20 ratio of Δ9-tetrahydrocannabinol (THC):cannabidiol (CBD) with the 
primary goal of evaluating the safety and tolerability of cannabidiol rich CBM for children 
with epilepsy.  
This study demonstrated that the CBM has low side effects in children. The 
researchers will conduct a larger clinical trial to demonstrate the efficacy of CBD as a 
treatment for epilepsy with approval from Health Canada.  Other objectives of the 
CARE-E study include evaluation of the pharmacokinetics of CBD and Δ9-THC, the 
efficacy of the CBM (measured by the decrease in duration and frequency of seizures), 
and the quality of life in participants dealing with refractory epileptic encephalopathy. 
The CARE-E study aims to provide evidence that CBD enriched CBM produces high 
therapeutic effects with low side effects. 
Seven participants have completed the CARE-E dose escalation study in 
Saskatchewan.2 All participants reported a reduction in seizure frequency starting at a 
dose of 5-6 mg/kg/day CBD-rich CBM, with four participants having >50% seizure 
frequency reduction. At 10-12 mg/kg/day, all participants have an average seizure 
frequency reduction of 74%, with five participants having >50% seizure frequency 
reduction. Of those 5 participants, 3 became seizure free. All participants continuously 
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maintained seizure reductions 3 months after weaning from the CBD rich CBM. The 
complete CARE-E study has not yet been published.  
The CARE-E study also monitored the safety and tolerability of the CBM. All 
participants reported side effects from the CBD rich CBM, including nausea, vomiting, 
diarrhea, increased appetite, and difficulty sleeping. However, these side effects were 
considered minor and did not increase with increasing doses of the CBD rich CBM.  No 
participants reported adverse effects related to THC consumption.  
 
2.2.9 Pharmacokinetics of cannabinoids in adults  
2.2.9.1 Absorption 
 
The route of administration can influence the time it takes for a drug to be 
effective, as well as the concentration of the drug found in the body. The most common 
route of administration of Cannabis is inhalation via smoking. Cannabinoids quickly 
absorb through the lungs, where it can diffuse from the alveoli directly to the 
bloodstream, and subsequently distribute to the brain.68 Because of the direct diffusion 
into the blood, cannabinoids can reach the target organs quickly, with pharmacological 
effects occurring in seconds to minutes.68 The peak effects of THC associated with 
inhalation can last for 15 to 30 minutes, before slowly decreasing and persisting for an 
additional 2 to 3 hours.69 Inhalation of THC and CBD exhibit high absorption; however, 
bioavailability varies due to factors such as puff duration, puff intervals, breath hold 
time, and depth inhalation.68 Inhalation bioavailability reported for THC varies from 10-
35%. CBD inhalation bioavailability is approximately 31%.70 Inhalation bioavailability is 
much higher than oral bioavailability due to first pass effects (i.e. the loss of drug prior to 
reaching the systemic circulation) observed with oral administration. Maximum plasma 
concentration at steady state (Cmax) and area under the curve (AUC) values higher in 
frequent smokers compared to occasional smokers, but time at which Cmax is observed 
(Tmax) remains the same.70  
Oromucosal administration undergoes rapid absorption though the mucosal 
membrane, providing higher plasma cannabinoid concentrations than oral 
administration but lower concentrations compared to inhalation administration.70 A 
portion of the dose may undergo oral absorption, which may reduce cannabinoid 
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bioavailability.71  Increased cannabinoid bioavailability is observed with food 
administration, with mean AUC and Cmax values 3-5 times higher than without food 
intake.70 
The absorption of cannabinoids varies with oral administration due to first pass 
metabolism.  For instance, THC can pass through the liver and undergo first pass 
metabolism to form 11-OH-THC, the main psychoactive metabolite. Additionally, CBD 
undergoes extensive first pass metabolism.72 Onset of pharmacological effects of THC 
occurs around 30-90 minutes, with peak effects at 2 to 3 hours, before decreasing and 
lasting for 4 to 12 hours.69 Blood concentrations of ingested THC reach 25-30% of 
levels following inhalation.23  
Oral is the principal route of CBD administration. Varying oral bioavailability is 
observed with CBD, ranging from 13-19%.53 Low bioavailability is due to poor solubility, 
first pass metabolism, and gastrointestinal degradation.70,73 Oral bioavailability can 
increase with increase in lipid formulation due to improved solubility or absorption via 
the lymphatic system.17 Transporters may play a role on the oral bioavailability of 
cannabinoids, such as P-gp efflux transporters, which are located in intestines, blood-
brain barrier, and blood-placental barrier. As a P-gp inhibitor, CBD may increase 
permeability of P-gp substrates, such as THC.53,74 Tmax of orally administered CBD 
varies from 1-4 hours, compared to inhalation Tmax of 0.6hr.70 Oral Tmax values higher 




The physicochemical characteristics of a drug determines how a drug is 
distributed in the body. Both CBD and THC are considered highly lipophilic compounds; 
therefore, they will be highly distributed in the highly vascularized and lipid-like tissues 
like adipose, heart, brain, mammary glands, liver, lungs, and the spleen.34,68 In the 
brain, higher 11-OH-THC levels are present compared to THC (only 1% of THC in 
systemic circulation reaches the brain), suggesting 11-OH-THC contributes significantly 
to the psychoactive effects associated with THC.34 THC is a substrate of P-gp 
transporter, undergoing efflux from the blood-brain barrier, limiting its permeability.74 
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Efflux transport can greatly affect THC effects by reducing brain concentrations. Due to 
high lipophilicity, cannabinoids will deposit into fatty tissues, leading to a slow and 
extended release of cannabinoids into the plasma over time. This, with the addition of 
enterohepatic recirculation, contributes to a larger volume of distribution of cannabinoids 
and a long half-life (CBD t1/2= 1-5 days; THC t1/2= 4.1 days).34,70 In adults, volume of 
distribution of CBD and THC ranges from 2.5 – 10 L/kg.34,72  
In general, THC and CBD display >95% binding to plasma proteins.72 This 
means that only 1-5% of total THC and CBD concentration is unbound and can exert 
pharmacological effects. Human serum albumin (600 μM in blood) is the most common 
plasma protein and is known to have 8 different binding sites with ability to bind 
endogenous and xenobiotic compounds.75 Serum albumin binds strongly to lipophilic 
and acidic drugs.76 This may include cannabinoids such as THCA and CBDA, 
cannabinoids that form THC and CBD through decarboxylation. Metabolites of THC, 
such as 11-OH-THC and THC-COOH, as well as their glucuronide forms bind largely to 
albumin.77 α1-Acid glycoprotein (AAG) binds tightly to basic and neutral drugs.76 As 
neutral cannabinoids, THC and CBD would likely bind to α1-acid glycoproteins (12-30 
μM). In some cases, diseases can affect albumin and AAG binding by decreasing the 
levels of albumin and AAG in the body or the binding ability or increasing AAG 
concentrations.75  
Cannabinoids do not actually bind to lipoproteins but instead partition into the 
lipid portion of the lipoprotein particle.76 More lipophilic drugs are found in the 
membrane lipids in comparison to water. In epileptic patients, immunoglobulin G (IgG), 
a major type of antibody, levels exist considerably higher than those in normal 
individuals.78 However, many cannabinoids have shown to suppress the levels of 
immunoglobulins, decreasing the immune response of the body.79 
Only the unbound fraction of cannabinoids (fu(b)) is pharmacologically active or 
has the ability to produce an effect. Considering the physicochemical characteristics of 
CBD and THC, plasma protein binding is high, therefore alterations of lipids and 
lipoproteins due to ketogenic diets may influence the cannabinoid fu(b).80 Increases in 
dietary fat intake may increase blood lipoprotein levels.80 Lipoproteins are a dynamic 
group of protein-lipid complexes that cannabinoids extensively bind to, ultimately 
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modifying the cannabinoid fu(b).81 Knowing the impact of fu(b) and bound fraction (f(b)) of 
cannabinoids can assist in dosage determinations.  
Cannabinoids exhibit non-specific binding, adsorption to certain plastics and 
membrane filters found in conventional plasma protein binding techniques, such as 
ultrafiltration and rapid equilibrium dialysis.82 Non-specific binding will cause inaccurate 




 The liver is the main contributor to the metabolism of THC and CBD, although the 
brain, small intestines, heart and lungs also play a role but with a lower contribution.34 
Cytochrome P450 (CYP) enzymes are located in the liver, intestine, kidney, lungs, 
heart, brain, and skin, with the highest expression found in the liver and intestines. 
When ingested, THC has a bioavailability of 6% due to first pass metabolism, which is 
considerably lower than inhalation, which has a bioavailability of 27%.83 Under CYP 
metabolism, THC undergoes oxidation to produce 11-OH-THC.83 As the primary 
metabolite, 11-OH-THC is considered to be more potent than its parent compound.23 
The main cytochrome P450 isoforms that play a role in the metabolism of THC to 11-
OH-THC are CYP2C9, CYP2C19, and CYP3A4.74 Additionally, 11-OH-THC can be 
metabolized into the inactive 11-nor-9-carboxy-THC (THC-COOH) by alcohol 
dehydrogenase or aldehyde oxygenase.69 Finally, THC-COOH can further undergo 
glucuronidation to be excreted in the urine.83   
 Due to its high lipophilicity, THC tends to remain in the body for a long duration. 
The elimination half-life of THC can range from 20-30 hours, with full elimination 
occurring in 13-30 days, depending on the frequency of Cannabis use.23,34 The majority 
of cannabinoids are excreted through the feces (~ 65%), while only 20% is excreted 
through the urine.69 Because THC is a highly lipophilic compound, it undergoes tubular 
reabsorption, therefore a low concentration of unchanged THC is found in the urine.34 
11-OH-THC is mainly excreted through feces while the inactive metabolite, THC-COOH, 
is excreted mainly through the urine as THC-COOH glucuronide via glucuronidation by 
UGT1A1 and UGT1A3.69,84 Considered to undergo rapid metabolism and excretion, 11-
 22 
OH-THC has a detection window of 3 days.74 The excretion half-life of THC-COOH is 
44-60 hours in the urine, displaying a much slower excretion rate.85 Due to a lower 
clearance, THC-COOH is considered a suitable diagnostic marker for the detection of 
Cannabis use. 
Over 100 metabolites have been identified for CBD.86 The main metabolic 
enzymes involved in CBD metabolism include CYP450 enzymes, 
glucuronosyltransferases, and sulfotransferases. Particularly, CYP1A1, CYP1A2, 
CYP2C19, CYP2D6, CYP3A4, CYP3A5, and CYP2A9 (minor) are the phase I enzymes 
responsible for producing the main monohydroxylated metabolites, 6-alpha-hydroxy 
cannabidiol (6a-OH-CBD), 6-beta-hydroxy-cannabidiol (6b-OH-CBD), 7-hydroxy-
cannabidiol (7-OH-CBD), and 7-carboxy-cannabidiol (7-COOH-CBD). The most 
abundant metabolite formed is 7-COOH-CBD.73,86  
At doses greater than 10 mg/kg, CBD may become dose-dependent, displaying 
nonlinear pharmacokinetics.73 Plasma concentrations of CBD disproportionally increase 
with dose, due to saturation of CYP enzymes. Interestingly, CBD can undergo self-
inhibition at high doses by inhibiting CYP2C and CYP3A enzymes, resulting in higher 
plasma concentrations than expected with linear pharmacokinetics.87 Metabolites 6a-
OH-CBD and 6b-OH-CBD may also contribute to the inhibition of CYP3A enzymes.73   
Furthermore, CBD and its hydroxylated metabolites can undergo phase II 
metabolism via the glucuronidation (major) or sulfation pathway, though majority of the 
glucuronidated metabolites derive from the parent cannabinoid.86 Enzymes UGT1A9, 
UGT2B7, and UGT2B17 play a major role in the glucuronidation of CBD, producing 
urinary metabolites CBD-glucuronide, 6-OH-CBD glucuronide and 7-OH-CBD 
glucuronide.84,88 The majority of CBD is excreted through feces, where a high amount of 
free CBD can be detected.88,89 Chronic oral administration of CBM displays a half-life 2-
5 days.70 
When co-administered with THC, CBD can competitively inhibit THC metabolism 
through competitive interaction of CYP enzymes.86 Previous studies have reported that 
a high concentration of CBD partially inhibits CYP metabolism of THC, resulting in slight 
decrease of the formation of 11-OH-THC through first pass metabolism and increase of 
THC levels in the plasma.72 
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2.3 Age dependent differences in pharmacokinetics and impact on 
dosage determination 
 
Little is known about the oral pharmacokinetics of cannabinoids in children. 
Children cannot be considered miniature adults, as there are many physiological 
differences between adults and children.90 High variability is found in the 
pharmacokinetics of children in general, due to the rapid physiological changes during 
development.91 Developmental maturation of physiological and biomedical processes is 
known to result in differences between children and adult drug pharmacokinetics.90 
Despite research on the pharmacokinetics of cannabinoids in adults, such data cannot 
be extrapolated to children, due to differences in body and organ size, route of 




Few studies discuss the differences of absorption in children, as most of the 
absorption effects of xenobiotics tend to focus on newborns and infants. The pH of the 
gastrointestinal tract does not reach adult values until the age of 3.92 Basic drugs are 
more rapidly absorbed in a child compared to adults.83 Intestinal transit time is 
considered to be shorter in children up to the age of 12 years compared to adults.91 
Immature gastrointestinal mucosal epithelium observed in infants can increase the 
bioavailability of xenobiotics.93 Gut microflora does not reach similar levels of adulthood 
until adolescence. In fact, the gut microflora levels are different in infants, children, and 
adults.92 Because of the immature gastrointestinal mucosal epithelium and the reduction 
of gut microflora, intestinal permeability is greater, enhancing the absorption of 
xenobiotics through the intestines and increasing the risk for toxic plasma 
concentrations in a child.92 Reductions in first pass metabolism due to immature 
development of the CYP and phase II enzymes seen in infants and toddlers also can 
result in higher concentration of unchanged drug in the systemic circulation.94 However, 
as CYP enzyme expression reach adult values by the age of 10, first pass metabolism 
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becomes comparable to adult capacity. This results in oral bioavailability variation 




The body composition of an individual can have a major impact on how a drug 
distributes in the body. Body fat, total body water, plasma protein levels, and muscle 
mass can determine the volume of distribution in an individual.91 In general, infants have 
a lower level of plasma proteins than older children. Additionally, plasma proteins in 
children mostly have a lower binding capacity.92 This means that there will be more 
unbound drug fraction distributing in the blood circulation and can diffuse to the target 
organs or be metabolized and excreted. However, plasma protein levels reach adult 
levels within a few years.91  
Changes in volume of distribution can impact drug pharmacokinetics. In infants, 
body water makes up 74% of the total body weight, decreasing to 55-60% when they 
reach adulthood.90 The high percentage of body water in infants results in a higher 
volume of distribution of water-soluble drugs as compared with adults.34  
Studies have shown that the blood brain barrier is not fully developed at birth, 
which makes the brain more vulnerable to xenobiotics.92 In fact, the brain does not fully 
mature until the age of 25.95  The brain of a child is proportionally large compared to 
their body, which can increase the distribution of xenobiotics to the brain.92 Studies have 
shown at 4-6 years of age, the central nervous system volume reaches 80-90% of the 
CNS volume in adults, yet body surface area reaches adult values at 16-18 years of 
age.92 With the addition of the under developed brain, this can result in different brain 
distribution characteristics relative to the adult.  
 
2.3.3 Metabolism  
 
Drug metabolism is an important process in detoxifying an active drug into an 
inactive metabolite that can be readily excreted from the body. Newborns and infants 
have low CYP mediated metabolism and low renal excretion, which can result in a drug 
exerting a greater potential of pharmacological or toxic effect.93 However, through early 
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childhood, CYP metabolism capacity can exceed the capacity of an average adult, 
which can either increase detoxification of several drugs or cause the drug to undergo a 
greater degree of bioactivation and create a more toxic compound.93 It is not until 
adolescence when enzyme activity reaches the same level as adulthood.91   
While most cytochrome P450 enzymes do reach full functional capacity early on 
in life, there are a few isoforms that very slowly develop. For instance, CYP1A2 
enzymes, which make up 13% of enzymes found in the liver, are known to metabolize 
antidepressants, antipsychotics, and polycyclic aromatic hydrocarbon (PAH) 
compounds. These enzymes reach 81% of adult values at 2 years of age.92 The major 
enzyme isoform in humans, CYP3A4, metabolizes about 50% of drugs.92 This isoform 
only reaches 50% adult values at 4-5 months of age and a developmental switch 
between the fetal CYP3A7 and adult CYP3A4 is observed in the first months of life.91 
Although CYP3A enzymes have a major role in metabolism, these enzymes develop 
early in life and may not produce major concerns if substrate overlap exists between 
CYP3A7 and CYP3A4.  
Another P450 enzyme important in xenobiotic metabolism is CYP2C19. This 
enzyme contributes to the metabolism of anticonvulsant and non-steroidal anti-
inflammatory drugs.92 This isoform does not reach comparable adult capacity until the 
age of 10.90 Enzymes involved in glucuronidation do not reach full functional capacity 
until 3 months to 3 years of age.92 This reduces the ability of a drug to become more 
water soluble and more readily excreted through the urine. The liver, the most important 
organ for metabolism, and the kidney, the most important organ for excretion, of infants 
are still immature, which can affect the functionality of metabolism and excretion. As 




Excretion is an important process to ensure that drugs and their metabolites are 
removed from the body, discontinuing the effects produced from these compounds. 
Immature drug excretion processes result in drug accumulation, which can increase the 
effects of drugs. Renal function increases with age due to an increase in renal blood 
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flow and decrease in renal vascular resistance.96 Renal blood flow increase is 
dependent on the increase in cardiac output.78 It takes about 2 to 3 years for renal 
function to reach maturation. 91  
The three main processes of renal excretion all reach full functional capacity at 
different rates. Glomerular filtration reaches full functional capacity by 6 months.91 
Tubular reabsorption does not reach adult values until 1-3 years.92 Tubular secretion 
does not reach full adult functional capacity until 7 months, but exceeds adult values in 
children and adolescents.92 With the different developmental rates of glomerular 
filtration, tubular reabsorption, and tubular secretion, this could cause difficulty in 
determining the renal excretion rate of a drug in children. An understanding the oral 
pharmacokinetics of drugs in children will aid in the development of age appropriate 
dosing regimens.  
  
 
2.4 A review of quantitative and qualitative cannabinoid analysis 
 
 
2.4.1 Matrices utilized in cannabinoid analysis 
 




Recreational Cannabis and Cannabis-based medicinal products come in various 
forms, including dried flower, fresh plant, oil extracts, edibles, and vapes. Often, 
Cannabis plant materials are analyzed for cannabinoid identification, quantification of 
cannabinoid concentration, potency, purity and quality control testing of regulated 
Cannabis products.97 Countries regulate the maximum amounts of cannabinoids, 
especially THCA and THC, present in Cannabis strains and products.94,98 The Cannabis 
industry often monitors original cannabinoid constituents (THCA, CBDA, and CBGA), 
which requires avoidance of decarboxylation during sample extraction and analysis.97,99  
 27 
In addition to cannabinoids, other components found in the Cannabis plant, such 
as terpenes, mycotoxins, trace metals and pesticides, are often quantified for 
pharmacological and toxicological purposes. 
 
Terpenes 
Terpenes are responsible for the scent and flavor of Cannabis plants and play a 
role in fragrance preference for certain Cannabis strains.100 Additionally, terpenes may 
possess therapeutic effects, though this is debatable amongst cannabinoid researchers. 
Termed “entourage effect”, cannabinoids and terpenes may provide a synergistic effect 
and aid in treating anxiety, depression, epilepsy, etc.100,101 Characterization and 
quantification of the 200 identified terpenes present in different Cannabis strains may 
provide more information on the possible effects of Cannabis use.101  
 
Mycotoxins 
Improper storage and humid environmental conditions can create a favorable 
situation for growth of fungi and bacteria on Cannabis plants.102 Fungi can produce 
secondary metabolites, termed mycotoxins. Aflatoxin, derived from the Aspergillus 
species, poses significant risks to humans, as it is considered to be carcinogenic.102,103 
Therefore, quantification of mycotoxins in Cannabis plants is pertinent to ensuring the 
safety of consumers. Under the Cannabis Act, regulated by Health Canada, all 
Cannabis plants must undergo aflatoxin testing, recommending limits set by the 
European Pharmacopeia of 2-12 µg/kg aflatoxin B1 and total of 4-15 µg/kg for aflatoxin 
B1, B2, G1, and G2.103  
 
Trace metals 
Trace metals, found in soil, rocks, pesticides, and fertilizer, can deposit and 
accumulate in Cannabis plants, potentially exposing consumers to metal toxicity.102 
Following the European Pharmacopeia and United States Pharmacopeia, Health 
Canada has set acceptable limits of arsenic, cadmium, lead, and mercury at sub µg/g in 






Pesticides aid in deterring unwanted pests from Cannabis plants, although 
pesticides pose a risk to humans, animals, and the environment.105 Quantification of 
pesticides is necessary to ensure levels are well within the regulatory requirements. 
Acceptable pesticide limits depend on the type of Cannabis product. Regulated by 
Health Canada, Cannabis industries must test for 96 pesticides, including myclobutanil, 
imidacloprid, deltamethrin, and carbofuran, with allowance of 0.02-3 µg/g pesticide in 
dried Cannabis flowers, 0.01-2.5 µg/g in oil, and 0.01-1.5 µg/g in fresh plants.104,105  
 
2.4.1.2 Biological matrices 
 
Th most commonly used biological matrices for cannabinoid analysis include 
whole blood, plasma, serum, urine, saliva and hair. These biological matrices are often 
used for forensic/toxicological testing, therapeutic drug monitoring, and pharmacokinetic 
studies. Blood (either whole blood, plasma, or serum) provides the most reliable 




 Recent Cannabis intake can be identified by detecting THC and THC-COOH and 
the urinary metabolites, THC glucuronide, and THC-COOH glucuronide, making it 
suitable for drug abuse analysis, driving under the influence (DUI) testing, and 
workplace testing.107 Urine analysis also provides information on cannabinoid 
metabolism.84-89 The use of urine is less invasive than venous blood collection. With 
chronic Cannabis use THC, 11-OH-THC, and THC-COOH may be detected in urine for 
up to 24 days.108 With occasional Cannabis use THC and THC-COOH urinary 
metabolites can detect intake within 6 hours of Cannabis consumption while THC, 11-






 Oral fluid testing is the most advantageous for roadside and workplace testing as 
it provides a non-invasive collection that can be collected on-site.109,110 Metabolite THC-
COOH provides an ideal marker for active drug use, as it is not present in Cannabis 
products (only present after metabolism) and has prolonged excretion.111 
Measurements of THC in oral fluids must be taken with precaution, to avoid THC 
contamination from oral fluid collection immediately after Cannabis consumption.109  
Both THC and THC-COOH may be detectable in oral fluid up to 48 hours and 29 
days, respectively.110 Detected only after Cannabis exposure, CBD and CBN may be 
possible markers for recent Cannabis exposure.112 Excluding the potential cannabinoid 
contamination immediately after Cannabis from residual cannabinoids in the oral cavity, 
oral fluid cannabinoid concentrations are comparable to plasma cannabinoid 
concentrations.111 Wide inter-individual variability exists for oral fluid detection due to 
amount and time duration of Cannabis consumption and body weight.110 Dry mouth, a 
common side effect with Cannabis consumption, can interfere and provide difficulty in 
collecting enough oral fluid volume in a timely manner.112,113 
 
Hair 
Hair has been used as a biological matrix for forensic cannabinoid testing, 
particularly to detect for chronic use of Cannabis.114 The route of administration is 
important in reliably analyzing hair for Cannabis consumption. Oral administration of 
Cannabis provides no detectable hair levels of THC or THCA, yet external 
contamination of THC and THCA due to side-stream smoke can result in false positives 
of Cannabis consumption.115,116 External contamination can be reduced by extensive 
washing of hair follicles prior to sample extraction; however, washing may not remove 
external contamination completely.114,115 THC-COOH provides more reliable testing as 







Blood specimens, including whole blood, plasma, and serum, are the most 
commonly used matrices for cannabinoid quantification and identification. These 
matrices are widely used in pharmacokinetic studies, tolerability and safety studies, 
therapeutic drug monitoring, workplace drug testing, DUI testing, and post-mortem 
analysis. Plasma cannabinoid concentrations provide information on total body 
cannabinoid exposure, necessary for determining pharmacokinetic characteristics of 
cannabinoids.  
Due to high plasma protein binding and low erythrocyte partitioning, blood-to-
plasma cannabinoid ratio for THC, 11-OH-THC, and THC-COOH is approximately 0.39, 
0.53 and 0.37, respectively.117 Based on the blood-to-plasma cannabinoid concentration 
ratio, cannabinoids are primarily isolated in the plasma. Use of whole blood for 
cannabinoid quantification may provide less sensitivity. Although whole blood analysis 
does not require prior plasma separation, plasma and serum samples provide better 
sensitivity in quantification of cannabinoids, as they contain less blood components and 
therefore less matrix effect or interference. Whole blood is susceptible to hemolysis, the 
rupturing of red blood cells, resulting in the release of hemoglobin and potassium into 
the plasma water.118 Plasma and serum are processed to remove blood cells, 
minimizing partial matrix effect. However, the main contributors of matrix effect in 
plasma and serum are plasma proteins and phospholipids. 
Plasma cannabinoid concentrations are more stable compared to whole blood 
cannabinoid concentrations. Whole blood cannabinoid concentrations vary in storage 
time periods. THC and CBD whole blood concentrations significantly decreased after 3 
months when stored at -20°C.119 Both 11-OH-THC and THC-COOH whole blood 
concentrations were stable until 26 weeks at -20°C. CBD, THC, 11-OH-THC, and THC-
COOH plasma concentration were all stable until 1 year at -20°C.119 If samples require 
reanalysis in the future, plasma provides better stability over blood.   
The Driving under the Influence of Drugs, Alcohol, and Medicines (DRUID) 
analysis requires the use of whole blood for forensic testing.117 However, blood analysis 
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requires on-site collection to preserve the cannabinoid concentration, as levels of 
cannabinoids can decrease rapidly.106 Venous blood collection requires sampling in a 
sanitary environment, which can delay collection time and potentially cause cannabinoid 
levels to reach well below the cut-off limit.120 Additionally, blood venous collection is 
invasive, has storage complications, and requires trained personnel for sampling.120,121   
 
Dried blood spot  
Dried blood spot (DBS) sampling has gained interest as an alternative for 
forensic testing. In fact, many US forensic laboratories implement the use of DBS for 
determining cannabinoid concentration in DUI testing. These labs have developed 
assays, using THC and 11-OH-THC as biomarkers for recent Cannabis exposure, due 
to their short half-lives, and THC-COOH as a biomarker for Cannabis exposure, as it 
usually remains in the body for several days.120,121 It is less invasive, requires low 
volume of blood, and provides safer transport and storage conditions compared to the 
traditional venous collection.120,122,123 DBS sampling also does not require complex 
preparation, such as addition of anticoagulant or plasma separation.124 DBS samples 
can be stored at room temperature for an extended period of time while analytes remain 
stable.122   
However, DBS has major disadvantages in quantitative analysis. Hematocrit 
(HCT) effect can interfere with accurate quantification of cannabinoids in DBS analysis. 
HCT, the volume of red blood cells in the blood, influences the viscosity of blood, 
affecting how the blood spot spreads on the card.125 Individuals have different HCT 
levels, therefore blood spot spread and the volume of blood that dries per unit of area of 
the card will vary. This variation can cause additional extraction issues related to matrix 
effects.125 DBS also undergo a chromatographic effect; more cells are concentrated in 
the center of the blood spot. Inconsistencies in distribution of the blood spot will cause 
issues with determining the punch area on the DBS card for sampling.  
DBS testing was developed in 1963 and initially targeted neonate screening, the 
so-called heel prick tests, for early detection of congenital disorders, such as 
phenylketonuria, sickle cell disease, and now cystic fibrosis.126 All newborns in Canada 
complete panels of heel prick tests typically within 24-48 hours after birth. These DBS 
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specimens are collected by pricking the heel of the newborn with a lancet and spotting 
the blood onto Whatman dried blood spot cards.  
Canadian provinces vary in terms of DBS storage time periods for future use. 
Quebec, Newfoundland, and Nova Scotia require neonate DBS storage for 1-5 years 
while British Columbia and Alberta store for 5-10 years. Saskatchewan, Manitoba, 
Ontario, and New Brunswick store DBS samples for at least 21 years.127 Researchers 
may access the cards if approved by research ethics boards; however, it raises 
concerns from the public on the nature of information that may come from the 
research.127 Nonetheless, research for the secondary use of DBS samples usually 
requires specimen deidentification. The neonate heel prick tests are mandatory in 
Canada through provincial legislation because the testing allows for rapid identification 
of affected neonates, initiation of treatments to prevent developmental delay, mental 
retardation, disease exacerbation or death.   
 
Plasma protein binding analysis 
 Unbound drug fraction (fu(b)), an essential pharmacokinetic parameter, is the only 
fraction of the drug that exerts pharmacological effects. Plasma protein binding assays, 
such as ultrafiltration, ultracentrifugation, and equilibrium dialysis can determine the fu(b) 
of a drug.128 Very few studies regarding plasma protein binding exist in the cannabinoid 
research area, with most plasma protein binding studies conducted, solely on THC and 
its metabolites, in the 1970s and 1980s.81,129,130 Plasma protein binding profiles of THC, 
11-OH-THC, and THC-COOH have been generalized for all cannabinoids, which must 
be cautioned, as plasma protein binding depends on the degree of lipophilicity and 
presence of a charge. Increase of plasma protein binding correlates to increase of 
lipophilicity.128 
Additionally, highly lipophilic compounds exhibit non-specific binding due to 
adsorption to the surfaces of plastic and membrane filters commonly found in the 
conventional plasma protein binding techniques such as ultrafiltration and rapid 
equilibrium dialysis.128 Cannabinoids display poor solubility to buffer solutions, an 
additional challenge with Rapid Equilibrium Dialysis (RED) analysis. Sethi et al. have 
developed a plasma protein binding assay that avoids the use of aqueous solvents and 
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materials associated with non-specific binding.131 This novel technique extracts the 
unbound, lipoprotein bound, and remaining plasma protein bound using isooctane, 2-
octanol, and acetonitrile, respectively.  
Isooctane, a non-polar solvent, creates a soluble environment for free 
cannabinoids. Isooctane is not miscible with water, producing a two-layer phase. 
Proteins are insoluble in isooctane; therefore, only the unbound fraction of cannabinoids 
is able to diffuse into the isooctane.131 Lipoproteins are soluble in 2-octanol, allowing 
cannabinoids bound to lipoproteins to diffuse into the solvent.132 Similar to isooctane, 2-
octanol is immiscible with water. Other plasma proteins, such as albumin and a-
glycoprotein, are not soluble in 2-octanol and will remain in the aqueous phase. 
Acetonitrile is miscible with water, forming a homogenous environment. The organic 
solvent will reduce the hydration layer around the remaining plasma proteins, 
misconfiguring the protein and releasing the bound cannabinoid.133  
  
The type of cannabinoid, matrix, and cannabinoid concentrations requires an 
understanding of each analytical technique, along with the advantages and 
disadvantages, to determine a suitable approach from accurate quantification and 
identification of cannabinoids.  
 
2.4.2 Different analytical techniques for quantitative and qualitative cannabinoid 
analysis 
 
Increased demand for Cannabis production prompts regulation of products 
deemed safe for consumption. Additionally, with arising potential therapeutic uses of 
Cannabis, researchers need to ensure the safety, tolerability, and efficacy of Cannabis 
products. Pharmaceutical and biomedical cannabinoid analyses require accurate 
quantitative (measurement) or qualitative (identification) assessment. 
 
2.4.2.1 Nuclear magnetic resonance spectroscopy 
 
Nuclear magnetic resonance (NMR) spectroscopy can determine the chemotype 
of certain Cannabis plants, or the variation of cannabinoid constituents present in the 
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plant.134 NMR can also confirm the structures of lesser known cannabinoids and newly 
discovered synthetic cannabinoids. This is an advantage over gas chromatography-
mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) 
techniques with limited mass spectral libraries.135 However, isolation of cannabinoids 
prior to NMR analysis can create difficulty, requiring extensive sample extraction, large 
volumes of sample, and specialized training.135  
 
2.4.2.2 Gas chromatography 
 
Gas chromatography (GC) is used for the quantitative and qualitative analysis of 
both Cannabis plant material and biological matrices. However, GC requires the use of 
high temperatures in the injector to convert sample to gas phase prior to 
chromatographic process. This can obstruct accurate measurement and detection of 
acidic cannabinoids, such as THCA and CBDA, as they can decarboxylate to their 
neutral cannabinoid forms, THC and CBD, from the high temperatures.136-138 
Derivatization of acidic cannabinoids, either silyation or esterification, can prevent 
decarboxylation, maintaining the acidic cannabinoids in plant or biological samples.138 
However, determination of total THC concentration (sum of THCA and THC 
concentration) quantification may benefit from GC analysis.136 
GC analysis requires volatility of analytes to properly undergo chromatographic 
separation, providing challenges for analysis of several synthetic cannabinoids.139 Low 
volatile synthetic cannabinoids undergo incomplete volatility and may require longer 
elution times, impeding high throughput analysis.140 
 
2.4.2.3 Liquid chromatography 
 
Another commonly used technique is high performance liquid chromatography 
(HPLC). Unlike GC, HPLC does not require the conversion of gas phase analytes via 
high temperatures, making it a suitable technique for acidic cannabinoids. The most 
commonly used technique for HPLC cannabinoid analysis is reverse phase (C-8 and C-
18 columns) liquid chromatography. The use of nonpolar stationary phase provides 
efficient separation of cannabinoids, a class of compounds with varying polarity. 
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However, reverse phase columns do not provide chiral separation, an issue for many 
cannabinoids that exist as enantiomers.141 Chiral columns can provide specificity 
between enantiomers.  pH of mobile phase is important for stable retention times of 
acidic cannabinoids, with pH at least 2 units lower than the pKa of the acidic 
cannabinoids.  
The most common detectors coupled to HPLC for cannabinoid analysis include 
ultraviolet (UV) detection, photodiode array (PDA) detection, fluorescence, and mass 
spectrometry. Typically, cannabinoids are present at high concentrations in Cannabis 
based products, making it more suitable to use HPLC-UV or HPLC-PDA compared to 
mass spectrometry.122,142,143 Biological cannabinoid samples typically use mass 
spectrometry as it provides sensitivity for quantification and identification of low 
cannabinoid concentrations. Multiple cannabinoid analysis requires a technique with 
high selectivity and specificity. Many cannabinoids have similar polarity characteristics, 
proving problematic for HPLC-UV.141 Cannabinoids can co-elute, resulting in 
overlapping peaks that will obstruct accurate peak area measurement. MS can 
differentiate cannabinoids based on mass-to-charge (m/z) ratios, allowing for greater 
selectivity. The high selectivity will lower the background noise and in turn provide 
greater sensitivity.  
Pharmacokinetic studies (cannabinoid metabolite formation, tolerability studies, 
therapeutic drug monitoring), cannabinoid stability studies, and toxicological testing 
requires quantification of low cannabinoid concentrations.144-146 Tandem mass 
spectrometry (coupling two mass analyzers) will provide selectivity by scanning for the 
m/z ratio of the ionized analyte (precursor ion) and its fragmentations (product ions). MS 
requires the use of stable isotope internal standards for accurate quantification. Internal 
standards can be expensive and may not be available for many of the lesser known 
cannabinoids.141 Nonetheless, LC-MS/MS provides the greatest sensitivity and 





2.4.3 Reverse phase liquid chromatography 
 
Liquid chromatography is a technique used to separate analytes from other 
analytes or endogenous/exogenous components found in the matrix, based on the 
physicochemical properties and the interaction with the mobile phase and stationary 
phase. It is important to separate analytes from each other or from other components in 
the matrix to reduce any potential interferences in quantitative analysis.  
Reverse phase is the most commonly used form of liquid chromatography, 
consisting of using a nonpolar stationary phase and polar mobile phase. The column, 
consisting of the nonpolar stationary phase, interacts with and adsorbs to the analyte.147 
Retention of the compound on the non-polar column is based on polarity. Non-polar 
analytes, such as THC and CBC, interact longer with the column, resulting in longer 
retention, while polar analytes, such as 11-OH-THC, have less interaction and elute off 
the column faster. Adjusting the mobile phase conditions and selecting an appropriate 
column is necessary to achieve optimal conditions for separation of cannabinoids. 
The mobile phase consists of two different solvents, comprised of aqueous 
(mobile phase A) and organic (mobile phase B) solvents. The type of solvents and pH 
modifiers used in LC-MS/MS analysis is critical. The type of mobile phase B plays a 
major role in the elution of your analyte. Acetonitrile and methanol are the two most 
commonly used organic solvents for mobile phase, with acetonitrile having higher 
elution strength compared to methanol, resulting in shorter retention times.147 However, 
this can be unsuitable if analysis involves multiple analytes, as overlapping peaks may 
occur. 
pH environment can dictate the degree of ionization of the analyte. pH levels 
below the pKa of the analyte may result in the analyte remaining in the nonionized form, 
leading to greater retention.148 pH levels above the pKa will produce ionized forms of 
the analyte. Ions have no or minimal interaction with the stationary phase, therefore will 
elute from the column earlier. pH levels within 2 units of the pKa can shift the analyte 
between the ionized and nonionized form, which will greatly impact the shift in retention 
time.148 Commonly used pH modifiers/buffers include ammonium formate, ammonium 
acetate, formic acid, and acetic acid. By controlling the pH with pH modifiers or buffers 
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can provide the method with better separation, retention and peak shape of the 
analytes.  
 
2.4.4 Triple quadrupole mass spectrometry 
 
Mass spectrometry is a technique used commonly for the quantification and 
detection of drugs and biological material. Triple quadrupole mass spectrometry (Figure 
2.2) is considered to be the ideal instrumentation to use for quantitative analysis due to 
its sensitivity and selectivity for both high and low mass molecules, consisting of two 
mass analyzers, used to select and scan for specific mass-to-charge ratios.149  
The first stage of mass spectrometry is the ionization of the analyte. For the 
detector to produce a signal from the analyte, the analyte must undergo desolvation and 
ionization.147 Electrospray Ionization (ESI), a commonly used atmospheric pressure 
ionization (API) technique, ionizes the analyte in the condensed phase by applying a 
voltage to the sample as it passes through the capillary of the electrospray probe, 
producing either positively or negatively charged ions.147 Polar, volatile solvents are 
necessary for ESI, due to better desolvation and lower surface tension.  
The mobile phase containing the analyte undergoes nebulization from a 
nebulizer gas applied down the probe, producing a fine aerosol of charged droplets. 
Temperature and a heater gas will aid in the desolvation of the analyte suspended in 
condensed phase, resulting in a gas phase ion. Once converted to a gas phase ion, 
now termed as a precursor ion, it will travel through the curtain plate employed with 
curtain gas, helping to prevent solvents and neutral molecules from entering the 
quadrupoles. As the precursor ions travel through the orifice plate, a declustering 
potential is applied to help gas phase ions dissociate from the charge droplets.150 
Finally, an ion guide helps focus the precursor ion into a tighter pathway, helping to 
increase the sensitivity of ions detected.  
The first and third quadrupole, the two mass analyzers, consist of a direct current 
(dc) and radio frequency (rf) potential, alternating between positive and negative 
potential, creating a spiral trajectory pathway.150 In the first quadrupole, the mass-to-
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charge (m/z) ratio of the precursor ion is selected, only allowing corresponding analytes 
to travel down the quadrupole.  
 
 
Figure 2.2. General schematic diagram displaying a triple quadrupole mass spectrometer, consisting of 
electrospray ionization (ESI) in positive ionization mode and channel electron multiplier (CEM) detector. 
 
Collision energy is applied between Q0 and Q2 to create a potential difference, 
causing the precursor ion to convert that energy to internal vibrational energy. The 
excited, unstable precursor ion travels to the collision cell, colliding with a collision 
activated dissociation gas (typically nitrogen or argon gas) to undergo fragmentation, 
forming product ions.150 After scanning for the selected product ions in the third 
quadrupole, a cell exit potential is applied to accelerate the ions to exit the third 
quadrupole to the detector. The product ions produce an electrical signal, amplified by 
the channel electron multiplier (CEM), a commonly used mass spectrometer detector.95 
The electrical signal produced by the ions is represented as peak intensity on a 
chromatogram.  
A technique, termed multiple reaction monitoring, is commonly used in triple 
quadrupole to increase the selectivity of the LC-MS/MS method by scanning for multiple 
product ions from a single or multiple precursor ions.150 Typically, the most abundant 
product ion, known as the quantifier ion, is used to measure the response and 
concentration of the analyte.149 The second product ion chosen is the qualifier ion, 







The CARE-E study will require collecting small volumes of plasma from pediatric 
patients using CBD rich CBM formulation for refractory epileptic encephalopathy to 
determine minimum plasma cannabinoid concentrations at steady state (Css,min), the 
lowest plasma concentration at steady state prior to administration of the next dose. 
CBM administered to the pediatric participants contains low THC levels. It is important 
to quantify THC concentrations in the plasma samples to determine if participant reports 
adverse, psychoactive effects associated with THC consumption. Quantification of 
Css,min requires development of a sensitive LC-MS/MS method.   
Several children with refractory epileptic encephalopathy administered Cannabis 
based medicine often are on a ketogenic diet. Ketogenic diets may alter lipoprotein 
production, potentially altering the plasma protein binding of cannabinoids. 
Understanding the plasma protein binding profiles and the effects of a ketogenic diet 
necessitates the development of an LC-MS/MS method that can accurately capture the 
unbound and bound cannabinoid fractions.  
Pharmacokinetic studies involve multiple blood sampling time points, typically 
over a time period of 24-48 hours, to capture the time course of total body exposure. 
Collection of large blood volumes and invasiveness of serial blood sampling in pediatric 
patients raises concerns on the practicality of using plasma for pharmacokinetic studies. 
Development of a DBS assay can provide a less invasive and lower sample volume 
collection for pediatric pharmacokinetic studies. As well, development of a DBS assay 
allows for assessment of maternal Cannabis exposure through the analysis of archived 
DBS samples obtained for mandatory neonatal screening testing.   
4 Overall purpose of study 
 
The overall purpose is to develop selective and sensitive LC-MS/MS analytical assays 
to quantify cannabinoids and metabolites in pediatric plasma, neonate dried blood spot, 





1. Minimum steady state cannabinoid concentrations will increase proportionally with 
increases in dose of a 1:20 THC:CBD CBM administered daily to children diagnosed 
with refractory epileptic encephalopathy. 
 
2. The 3-solvent extraction technique will provide more accurate quantification of the 
unbound and bound fractions of CBD, THC, 11-OH-THC, and CBC with no to 
minimal non-specific binding, compared to the traditional plasma protein binding 
assays.  
 
3. Legalization of recreational Cannabis will result in an increased prevalence of 




This study aims to: 
 
1. Develop and validate an LC-MS/MS method for the quantification of bioactive 
cannabinoids in plasma of pediatric patients on Cannabis 1:20 THC:CBD herbal 
extract therapy. 
 
2. Quantify minimum cannabinoid concentration at steady state (Css,min) in plasma 
samples of pediatric patients in the CARE-E study. 
 
3. Conduct a comparative analysis for the determination of plasma protein binding 
characteristics of CBD, THC, 11-OH-THC, and CBC using ultrafiltration, rapid 
equilibrium dialysis, and a newly adapted 3-solvent extraction technique. 
 
4. Develop and validate a dried blood spot assay to determine the prevalence of 





The CARE-E (15-192) and Prevalence of Prenatal Cannabis (17-319) Studies 
were approved by the University of Saskatchewan Biomedical Research Ethics Board 
(Appendix I). Consent for the enrollment of pediatric patients was obtained through their 
legal guardians for the CARE-E Study. Collection of provincial neonate DBS samples 
and venous blood collection from participants was approved for the prenatal Cannabis 
study.  
6 Materials and Methods 
 
Chemicals and Reagents 
 
CBD (cat no. C-045), THC (cat no. T-005), 11-OH-THC (cat no. H-027), THC-
COOH (cat no. T-010), and CBC (cat no. C-143) stock standards were purchased from 
Cerilliant (Round Rock, TX) at a concentration of 1 mg/mL, dissolved in methanol. CBD-
d3 (cat no. C-084), THC-d3 (cat no. T-003), 11-OH-THC-d3 (cat no. H-04), and THC-
COOH-d3 (cat no. T-004) internal standards were also purchased from Cerilliant 
(Round Rock, TX) at a concentration of 0.1 mg/mL dissolved in methanol. CBC-d9 (cat 
no. 21294) was purchased from Cayman Chemicals (Ann Arbor, MI). All stock and 
internal standards were stored at -20°C until use. Fisher Scientific Optima™ LC/MS 
grade acetonitrile (cat no. A9551), LC/MS grade water (cat no. W64), LCMS grade 
methanol (cat no. A45564), and LCMS grade formic acid (cat no. A11750) were 
purchased from ThermoFisher Scientific (Whitby, ON).  
 
 
Human Plasma  
 
Citrated human plasma used was obtained from the Canadian Blood Services 
(Human Biomedical Ethics approval was obtained for using this blood). Pharmacokinetic 
studies used lithium heparin plasma. Whole blood used for the dried blood spot method 
development and validation was obtained from volunteers, with ethics approval, and 






Eppendorf™ Protein LoBind microcentrifuge tubes (cat no. 022431081), 
disposable borosilicate glass tubes, Pasteur pipettes, 15 mL polypropylene centrifuge 
tubes, and SureOne micropipette tips were purchased from Fisher Scientific (Hampton, 
NH). Agilent 2 mL amber autosampler vials (Santa Clara, CA) were used to store stock 
and internal standards as well as for LC-MS/MS analysis. Agilent 200 μL HPLC flat 
bottom inserts (Santa Clara, CA) were used for LC-MS/MS analysis. Pasteur pipettes 
(cat no. 13-678-6G) were purchased from Fisher Scientific. Thermolyne™ Dri-bath™ 
was purchased from Thermo Fisher Scientific. BD Vacutainer® Barricor™ (Mississauga, 
ON) blood sample collection tubes were gifted through Becton Dickinson (Franklin 
Lakes, NJ).  Centrifree Amicon Ultrafiltration Devices with Ultracel PL membranes (cat 
no. 4104) were purchased from Millipore (Billerica, MA). Rapid Equilibrium Dialysis plate 
(cat no. 90006) was purchased from Thermo Fisher Scientific. Beckman® Coulter 
Allegra® 25R Refrigerate Benchtop Centrifuge with rotor A-15 was used for the 
ultrafiltration study. Whatman 903 Protein Saver cards were purchased from VWR 
(Radnor, PA). Captiva EMR-Lipid 1 mL 96-well plates (cat no. 5190-1001), Captiva 1 
mL 96-well deep collection plates (cat no. A69600100), and vacuum collar (cat no. 




 LC-MS/MS analysis was conducted using an Agilent 1290 Infinity liquid 
chromatography instrument with binary pumps (Santa Clara, CA) coupled to a SCIEX 
QTrap 6500 mass spectrometer (Concord, ON). The Agilent Zorbax Eclipse XDB-C18 
Narrow Bore 2.1 x 75mm, 3.5-micron column and Zorbax Eclipse XDB-C8 Narrow Bore 
2.1 x 12.5 mm, 5-micron guard column were purchased from Agilent (Santa Clara, CA). 
 
Software 
 SCIEX Analyst® 1.6.2 and 1.7 was used to perform instrumental control, 
compound optimization, parameter optimization and data acquisition. SCIEX 
MultiQuant™ 3.0.1 was used to perform quantitation analysis. 
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7 Development and Validation of a LC-MS/MS Method for the 
Quantification of Bioactive Cannabinoids in Plasma of 
Pediatric Patients on Cannabis herbal extract Therapy 
 
7.1 Method Development 
 
The initial conditions of the method originated from peer-reviewed literature. The 
LC-MS/MS method was previously developed by two graduate students, Ahmed 
Almousa and Muath Helal, in the Alcorn lab group. Initially, the LC-MS/MS method 
consisted of a 5-minute isocratic sample run time, held at 10% mobile phase A and 90% 
mobile phase B with a flow rate of 250 µL/min. The LLOQ was set to 0.98 ng/mL.  
As depicted in Figure 7.1a, the 11-OH-THC and CBD peaks overlapped. Although 
the two cannabinoids have different MRM transitions, both potentially interfered with 
each other, causing a potential matrix effect. It is important to ensure good separation 
between each analyte to avoid confounding interferences. Method optimization can be 
completed by modifications to mobile phase composition, flow rate, and sample 
extraction. 
 The initial method (isocratic method of 250 µL/min of 10% mobile phase A and 
90% mobile phase B for 5 minutes) resulted in overlapping 11-OH-THC and CBD 
peaks. To resolve this issue, a gradient method was substituted for isocratic delivery of 
the mobile phase (Figure 7.1b). After optimization, the gradient conditions for LC-
MS/MS analysis were as followed: 80% B from 0-3.5 minutes, increasing to 90% B until 
10 min, and returning to 80% B over 10.5-13.5 min.  
 Initially, the flow rate of the LC-MS/MS assay was set to 250 µL/min. Use of 
higher flow rate, 700 µL/min, allowed a return to isocratic conditions, with mobile phase 
composition optimized to 77.5% B. These changes allowed the sample run time to 
shorten to 10 minutes and maintained adequate separation of 11-OH-THC and CBD 
(Figure 7.1c). 
 Modifications to the sample extraction method further increased sensitivity. 
Following protein precipitation, 700 µL of supernatant was dried using a dry bath with 
filtered air and reconstituted with 200 µL mobile phase (22.5% A: 77.5% B v/v). Peak 
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intensity of 11-OH-THC, CBD, THC, and CBC at 0.98 ng/mL, with the initial LC-MS/MS 
conditions, were 2.6 x 103, 6.9 x 103, 3.8 x 103, and 2.1 x 103, respectively. After the 
addition of drying and reconstituting to the sample extraction method, peak intensities 
increased to 1.1 x 104, 2.1 x 104, 9.2 x 103, and 6.2 x 103 for the respective 
cannabinoids. Increase of peak intensity allowed for a lower LLOQ of 0.49 ng/mL.  
 
 
Figure 7.1. LC-MS/MS method optimization, showing efficient separation and increased sensitivity with 
modifications to mobile phase composition, flow rate, and sample extraction with a) initial LC-MS/MS 
conditions of an isocratic method running for 5 minutes with flow rate of 250 μL/min, b) gradient method 
running for 13.5 minutes with flow rate of 250 μL/min, and c) final LC-MS/MS isocratic method running for 























Stock and working standard solution preparation 
Stock solution of 5000 ng/mL was prepared by adding 20 μL of 1 mg/mL CBD, 
THC, 11-OH-THC, THC-COOH, CBC, and CBN each to 3880 μL methanol. Eight 
working standard concentrations were prepared, 9.77, 19.53, 39.06, 78.12, 156.25, 625, 
1250, and 2500 ng/mL. The lowest limit of quantification (LLOQ) was determined from a 
signal-to-noise ratio ³ 5. Four working standards, ranging from 156.25-2500 ng/mL, 
were prepared by parallel dilution from the original stock solution with methanol. The 
remaining 4 working standards, 9.8-78.12 ng/mL, were prepared by serial dilution from 
the 625 ng/mL working standard.  
Quality control concentrations were determined according to the standard curve. 
The lowest quality control (LQC) must be within 3 times the LLOQ, the middle quality 
control (MQC) approximately 50% of the standard curve range, and the highest quality 
control (HQC) within 75% of the upper limit of quantification (ULOQ). The LQC for CBD, 
THC, 11-OH-THC, and CBC was 1.40 ng/mL. The MQC and HQC for CBD, THC, 11-
OH-THC, and CBC were 50.56 ng/mL and 101.2 ng/mL, respectively. All standards and 
quality controls were prepared in amber autosampler vials, wrapped with parafilm, and 
stored at -20°C.  
 
Internal standard preparation 
100 μg/mL CBD-d3, THC-d3, 11-OH-THC-d3, THC-COOH-d3, and CBC-d9 
stock solutions were diluted in methanol to prepare a 100 ng/mL working internal 
standard solution. Internal standards were prepared in amber autosampler vials, 
wrapped in parafilm, and stored at -20°C. On day of analysis, 10 μL of 100 ng/mL was 
added to 600 μL acetonitrile for protein precipitation, with a final internal standard 
concentration of 1.64 ng/mL.  
 
Sample preparation procedure 
For standards and quality controls, 10 μL of analyte was added to 190 μL blank 
human plasma. For the double blank and blank samples, 10 μL of methanol was added 
to 190 μL blank human plasma. 10 μL of methanol and 600 μL of cold acetonitrile was 
added to the double blank sample. 610 μL of cold (4°C) acetonitrile spiked with internal 
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standard (1.64 ng/mL) was added to the blank, standard and quality control samples in 
Eppendorf Lo-bind microcentrifuge tubes. All samples were mixed thoroughly by vortex 
mixing. Samples were centrifuged at 14000 rpm for 10 minutes at 4°C. 700 μL of 
supernatant was transferred to borosilicate culture tubes and dried with filtered air at 
35°C for 20 minutes using dry bath, followed by reconstitution with 200 μL of mobile 
phase (77.5% mobile phase B: 22.5% mobile phase A; refer to liquid chromatography 
conditions below). Samples were then transferred to HPLC inserts in amber 
autosampler vials and readied for mass spectrometric analysis.  
 
Liquid chromatography conditions 
Method development and validation experiments utilized the Agilent 1290 Infinity 
LC System with a Zorbax Eclipse XDB-C18 Narrow-Bore 2.1 x 75 mm 3.5-micron 
column and Zorbax Eclipse XDB-C8 Narrow-Bore 2.1 x 12.5 mm 5-micron guard 
column, both controlled at 30°C, with an isocratic flow rate of 700 μL/min for 10.5 
minutes. Mobile phase comprised of 77.5:22.5 (% v/v) of methanol and water containing 
0.1 mM ammonium formate. The autosampler temperature was controlled at 4°C with a 
sample injection volume of 5 μL.  
 
Mass spectrometry conditions 
The mass spectrometric instrument consisted of a SCIEX QTrap® 6500 triple 
quadrupole mass spectrometer (Washington, DC), equipped with TurboIonSpray® 
electrospray (ESI) interface, with ionization spray voltage set to 5500 V in positive 
ionization mode. Multiple reaction monitoring (MRM) conditions and mass spectrometer 
conditions, outlined in Table 7.1 and 7.2, were optimized. Triple quadrupole mass 








Table 7.1. Multiple Reaction Monitoring (MRM) conditions for the identification and quantification of CBD, 
THC, 11-OH-THC, and CBC in human plasma 













Exit Potential  
(V) 
CBD 
Quantifier 315.1 193.2 50 61 25 12 
CBD 
Qualifier 315.1 259.2 50 61 19 14 
CBD-D3 
318.1 196.1 50 56 29 12 
THC 
Quantifier 315.1 193 50 91 31 12 
THC 
Qualifier 315.1 259.2 50 96 31 10 
THC-D3 








331.1 105.0 50 66 41 12 
11-OH-
THC-D3 334.1 196.1 50 66 41 12 
CBC 
Quantifier 315.1 193.2 50 61 25 12 
CBC 
Qualifier 315.1 259.2 50 61 19 14 
CBC-D9 
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7.2 Method Validation 
 
Method validation involved the assessment of selectivity, linearity, intra- and 
inter-day accuracy and precision, carryover, stability of analytes, and matrix effect 
conducted over 3 days, following the 2018 FDA Bioanalytical Method Validation 
Guidance for Industry.151 
 
7.2.1 System Suitability  
 
 System suitability was analyzed in five repeated injections of a 50 ng/mL 
standard in methanol to determine the performance and reproducibility of the LC-
MS/MS assay and instrumentation. Mean peak area and standard deviation of each 
cannabinoid were calculated to determine the coefficient of variance (CV). No system 
suitability criterion was established in the FDA Bioanalytical Method Validation 
Guidance for Industry. However, MDS Pharma Services (MDSPS) has established a 




Selectivity was analyzed in 6 individual lots of blank human plasma to determine 
the absence of co-eluting compounds with the analytes of interest. Plasma sources 






To determine linearity, standard curves (ranging from 0.49 - 125 ng/mL) were 
prepared each day of method validation. Standard curves were assessed with weighted 
linear regression analysis of 1/x. Following FDA bioanalytical method validation 
guidelines, the coefficient of determination (R2), analysis of how close the observed 
standard curve points are to the fitted regression line, must be greater than or equal to 
0.98.  Accuracy of the LLOQ and remaining standard curve points require observed 
concentration within ±20% and 15% of the nominal concentrations, respectively. 
 
7.2.4 Intra- and Inter-day Accuracy and Precision 
  
Intra- and inter-day accuracy and precision were assessed by analysis of 6 
replicates of the LLOQ, LQC, MQC, and HQC concentrations over the course of 3 
separate days. FDA guidelines accept intra- and inter-day accuracy and precision of 
LLOQ and QC observed concentrations within ± 20% and 15% of the nominal 




	× 100%               Equation 7.1 
 
Intra- and interday precision of replicates were calculated using percent relative 
standard deviation (RSD), as stated in the equation 7.2: 
 
																									𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛	(𝑅𝑆𝐷%) 	= 	 2,-+'-%'	'$&.-,.*+	*3	%$41.)-,$#
5$-+	)*+)$+,%-,.*+	*3	%$41.)-,$#
	× 	100%       Equation 7.2 
 
7.2.5 Ion Ratios 
 
 Ion ratios, determined by the peak area intensity of the qualifier ion relative to the 
peak area intensity of the quantifier ion (Equation 7.3), confirm the presence of specific 
cannabinoids and assess for any interferences that may produce inaccurate 
quantification. All standard curve and quality control samples from method validation 
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were used to evaluate consistency of the ion ratios for each cannabinoid. No criteria on 
the acceptable ion ratio precision has been established in the FDA guidelines.  
 
																																																𝐼𝑜𝑛	𝑟𝑎𝑡𝑖𝑜	 = 	 6$-7	-%$-	*3	89-1.3.$%	.*+
6$-7	-%$-	*3	89-+,.3.$%	.*+




To determine potential carryover of analyte from the previous injection, an ULOQ 
of 125 ng/mL sample was injected followed by an injection of a double blank (plasma 
sample with no analyte or internal standard) Carryover analyte should be less than 20% 
of the peak area of LLOQ and less than 5% of the peak area of internal standard.  
 
7.2.7 Stability  
 
Short-term stability (unprocessed and processed)  
 Occasionally, clinical samples may be left at room temperature in the laboratory 
setting for several hours, leading to potential instability or degradation of the analyte.  
Stability tests determine whether or not the analyte was stable in these conditions and if 
unstable, conditions need optimization to ensure the analyte was not compromised. 
Short-term stability was assessed by storing processed (extracted) and unprocessed 
samples on bench-top at room temperature for 6 hours. 6 replicates of LQC (1.40 
ng/mL), MQC (50.6 ng/mL), and HQC (101.2 ng/mL) were analyzed for both 
unprocessed and processed conditions.  
 
Long-term stability 
 Long-term stability covers the time period where reanalysis of study samples 
may be needed. To assess long-term stability of the analytes, 6 replicates of LQC, 
MQC, and HQC were prepared and stored at -80°C for analysis at 1, 2, 3, 6, and 12 
months from the start of method validation. Samples were stored in the dark to prevent 
photodegradation of cannabinoids. 
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Freeze thaw stability 
 Freeze thaw stability was conducted using 3 sets of 6 replicates of the LQC (1.40 
ng/mL), MQC (50.6 ng/mL), and HQC (101.2 ng/mL) to determine if analytes of interest 
were stable under a cycle of varying temperature conditions. All sets were stored at -
80°C. After 24 hours, all samples were thawed at room temperature, with only one set 
analyzed and the remaining sets placed in -80°C for another 24 hours then thawed at 
room temperature. A maximum of three freeze thaw cycles were performed. First day of 
accuracy and precision samples were used as time 0 for freeze thaw stability.  
  
Autosampler stability 
 Autosampler stability determines the stability of analytes of interest under the 
HPLC autosampler conditions, such as resident time and temperature. To assess 
autosampler stability of CBD, THC, 11-OH-THC and CBC, the standard curve and 
replicates of the LLOQ and QCs from the previous day of method validation were stored 
in the autosampler at 4°C and reinjected 24 hours after first injection. 
 
7.2.8 Matrix effect studies 
 
 Matrix effect studies investigates the extraction efficiency, matrix factor, and 
recovery of the analyte based on sample preparation and the matrix. These models 
investigate how well the analyte can be recovered through sample extraction (extraction 
efficiency and recovery) and the possible interference of endogenous compounds in the 
matrix (matrix factor). 
Six replicates of pre-spike, post-spike, and pure spike at the LQC (1.40 ng/mL) 
and HQC (101.2 ng/mL) concentrations were used to determine extraction efficacy, 
matrix factor, and recovery of analytes of interest. For pre-spike, 10 μL of working 
standard was added to 190 μL human plasma. Samples were subsequently processed 
following the sample extraction procedure. For post-spike, 10 μL of methanol was 
added to 190 μL human plasma. 610 μL of cold acetonitrile and internal standard was 
added to the samples. Following protein precipitation, samples were centrifuged at 
14000 rpm for 10 min at 4°C. 8.7 μL of working standard was added to 691.3 μL of 
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supernatant. Samples were then dried using filtered air and reconstituted with mobile 
phase. For pure-spike, 10 μL of working standard and 8.7 μL of internal standard was 
added to 182.7 μL of mobile phase.   
Extraction efficiency, matrix factor, and recovery were calculated from the peak 
area ratio of the analytes, using Equations 7.4-7.6. Extraction efficiency is calculated 
using pre-spike samples (fortified with analyte prior to extraction) and pure-spike 
samples (fortified with analyte in mobile phase), indicating any loss/interference of 
cannabinoids during extraction in the presence of endogenous compounds. Matrix 
factor is calculated using post-spike samples (fortified with analyte after extraction) and 
pure spike samples, determining potential interferences between endogenous 
compounds and cannabinoids in the absence of extraction limitations. Recovery is 
calculated by comparing pre-spike samples and pure-spike samples, where post-spike 
samples represent 100% recovery of cannabinoids. Comparison of peak area ratios 
between the analyte and internal standard were assessed to determine if the internal 
standard compensated for any cannabinoid loss through sample preparation. 
 
																				𝐸𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛	𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦	(%) 	= 	 6$-7	-%$-	*3	4%$:#4.7$
6$-7	-%$-	*3	49%$	#4.7$
	× 	100%	         Equation 7.4 
 
																														𝑀𝑎𝑡𝑟𝑖𝑥	𝑓𝑎𝑐𝑡𝑜𝑟	(%) 	= 	 6$-7	-%$-	*3	4*#,:#4.7$
6$-7	-%$-	*3	49%$	#4.7$
	× 	100%              Equation 7.5 
 
																																						𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦	(%) 	= 	 6$-7	-%$-	*3	4%$:#4.7$
6$-7	-%$-	*3	4*#,:#4.7$




We have developed a sensitive, specific, robust, precise, and accurate LC-MS/MS 
method for the quantification of bioactive cannabinoids in human plasma. We obtained 
a standard curve ranging from 0.49 ng/mL - 125 ng/mL for 11-OH-THC, CBD and THC, 
and 0.98 ng/mL - 125 ng/mL for CBC, with acceptable linearity.  The lowest limit of 
quantification (LLOQ) for CBD, THC, and 11-OH-THC was 0.49 ng/mL and 0.98 ng/mL 
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for CBC. Retention times for 11-OH-THC, CBD, THC, and CBC were 1.83 min, 2.19 
min, 5.55 min and 8.50 min, respectively (Figure 7.2). 
 
 
7.3.1 System Suitability 
 
 Analysis of the repeated five injections of a 50 ng/mL 11-OH-THC, CBD, THC, 
and CBC methanol solution showed consistency in the peak areas obtained. Day to day 
variation could be seen in the mean peak areas (Table 7.3), which could be influenced 
by many factors, such as temperature, humidity, multiuser instrumentation, etc. 
However, all cannabinoid intraday CV values ranged from 0.76 to 3.77% throughout the 
three days of method validation, all within the MDSPS CV criteria of less than 6%.  
  
Table 7.3. System suitability data of 11-OH-THC, CBD, THC, and CBC, showing the mean peak area of 
five repeated injections of a 50 ng/mL concentration and acceptable CV (%) of less than 6%.  
 Day 1 Day 2 Day 3 
 Peak Area 
(mean ± SD) 
CV (%) Peak Area 
(mean ± SD) 
CV (%) Peak Area 



































Figure 7.2. Chromatogram depicting the retention times of the quantifier ions for 11-OH-THC (1.83 min), 




















 Analysis of the 6 individual blank human plasma lots showed no co-eluting peaks 
at the same retention times of 11-OH-THC, CBD, THC, and CBC (Figure 7.3). A peak 
with the same MRM transitions as the quantifier ions of CBD, THC, and CBC was 
detected; however, did not interfere with the quantification of the cannabinoids as it 
eluted at 3.05 minutes. Additionally, the peak was not present in the qualifier ion 
transition for CBD, THC, and CBC.  
 
Figure 7.3. Chromatograms displaying the 6 blank individual sources of human plasma used in the 
method validation to determine the selectivity of the LC-MS/MS method. An unknown peak detected at 
3.05 minutes has the same MRM transitions as the CBD, THC, and CBC quantifier ions but not detected 
in the qualifier ion. The unknown peak does not elute at the same retention times of the cannabinoids, 




 Standard curves prepared in pooled human plasma, with concentrations of CBD, 
THC, and 11-OH-THC ranged from 0.49-125 ng/mL and 0.98-125 ng/mL for CBC, 
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displayed linearity (R2 ³ 0.98) during the 3 days of method validation (Figure 7.4). The 
lowest R2 value achieved during method validation was 0.9969 in 11-OH-THC.  The 
slopes of CBD, THC, 11-OH-THC, and CBC demonstrated consistency throughout 
method validation, with averages of 0.1416 ± 0.0047, 0.1602 ± 0.0057, 0.2092 ± 
0.0093, and 0.1665 ± 0.0064, respectively. All standard curve points were within the 
acceptable criteria of accuracy. 
 
Figure 7.4. Standard curves of CBD, THC, 11-OH-THC, and CBC, during the 3 days of method validation, 
showing linearity with R2 values ³0.98. CBD, THC, and 11-OH-THC have 8 standard points, ranging from 
0.49-125 ng/mL. CBC has 7 standard points, ranging from 0.98-125 ng/mL. Standard curves are 
weighted 1/x to improve the regression fit of the low concentration standards. 
 
7.3.4 Inter- and intraday accuracy and precision 
 
 All LLOQ and QC replicates over the course of 3 days remained within 
acceptable criteria.  Intraday accuracy and precision data of CBD and THC were 
displayed in Table 7.4 while 11-OH-THC and CBC were displayed in Table 7.5. Interday 
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accuracy and precision of all cannabinoids over the 3 days were displayed in Table 7.6. 
The lowest accuracy and most variation in precision were shown in the LLOQ of all four 
cannabinoids, particularly in CBD.  
 
Table 7.4. Intraday accuracy and precision of LLOQ, LQC, MQC, and HQC for CBD and THC for each of 
the 3 days of method validation. Accuracy and precision of observed LLOQ and QC concentrations must 
be within 20% and 15% of the theoretical concentrations, respectively (n=6). 
 CBD THC 




















1 0.43 ± 0.03 6.98 85.62 0.47 ± 0.04 8.51 93.47 
2 0.44 ± 0.04 9.09 89.97 0.48 ± 0.07 14.58 97.76 
3 0.42 ± 0.03 7.14 86.54 0.44 ± 0.02 4.55 90.53 
1.40 
(LQC) 
1 1.47 ± 0.06 4.08 101.15 1.48 ± 0.03 2.03 106.02 
2 1.39 ± 0.07 5.04 99.48 1.46 ± 0.06 4.11 104.59 
3 1.41 ± 0.03 2.13 101.04 1.41 ± 0.07 4.96 100.90 
50.56 
(MQC) 
1 51.57 ± 0.99 1.92 101.99 50.26 ± 0.59 1.17 99.40 
2 50.59 ± 0.55 1.09 98.99 50.60 ± 0.60 1.19 100.09 
3 53.10 ± 0.52 0.98 105.03 53.53 ± 0.91 1.70 105.88 
101.20 
(HQC) 
1 114.26 ± 1.75 1.53 112.90 114.74 ± 2.21 1.93 113.38 
2 99.37 ± 1.14 1.15 98.19 99.21 ± 3.20 3.23 98.03 
3 104.05 ± 2.46 2.36 102.81 107.72 ± 4.24 3.94 106.44 
 
 
Table 7.5. Intraday accuracy and precision of LLOQ, LQC, MQC, and HQC for 11-OH-THC and CBC for 
each of the 3 days of method validation. Accuracy and precision of observed LLOQ and QC 
concentrations must be within 20% and 15% of the theoretical concentrations, respectively (n=6).  
 11-OH-THC CBC 





















1 0.47 ± 0.02 2.26 101.55 - - - 
2 0.46 ± 0.05 10.87 93.85 - - - 
3 0.47 ± 0.04 8.51 96.25 - - - 
0.98 
(LLOQ) 
1 - - - 0.94 ± 0.04 4.26 98.83 
2 - - - 0.94 ± 0.04 4.26 95.93 
3 - - - 0.87 ± 0.06  6.90 83.63 
1.40 
(LQC) 
1 1.53 ± 0.05 3.27 109.39 1.35 ± 0.05 3.70 96.25 
2 1.45 ± 0.05 3.45 103.53 1.39 ± 0.05 3.60 99.33 
3 1.38 ± 0.06 4.35 98.63 1.24 ± 0.05 4.03 88.79 
50.56 
(MQC) 
1 50.82 ± 1.99 3.92 100.52 50.82 ± 0.89 1.75 100.51 
2 51.70 ± 0.37 0.72 102.25 51.45 ± 0.51 0.99 101.77 
3 53.55 ± 0.71 1.33 105.91 54.15 ± 0.53 0.98 107.09 
101.20 
(HQC) 
1 113.58 ± 4.37 3.85 112.23 116.29 ± 2.55 2.19 114.91 
2 100.56 ± 3.53 3.51 99.37 99.85 ± 2.05 2.05 98.66 




Table 7.6. Interday accuracy and precision data of LLOQ, LQC, MQC, and HQC for CBD, THC, 11-OH-
THC, and CBC over the 3 days of method validation. Accuracy and precision of observed LLOQ and QC 









































51.46 ± 1.65 3.21 101.79 
HQC 
(101.20) 













52.02 ± 1.65 3.17 102.89 
HQC 
(101.20) 













51.95 ± 1.76 3.39 103.12 





7.3.5 Ion Ratios  
 
 Assessment of the ion ratios for the standard curve and quality control samples 
of CBD, THC, 11-OH-THC, and CBC during method validation determined precision of 
ion ratios (Table 7.7). Consistency was identified within and between days of analysis, 
with average ion ratios of 0.33, 0.60, 0.94, and 0.50 for CBD, THC, 11-OH-THC, and 
CBC, respectively.  
 
Table 7.7. Ion ratio precision of CBD, THC, 11-OH-THC, and CBC, comparing the peak areas of the qualifier ions and 
quantifier ions of intraday (n=12) and interday (n=36) samples during method validation 
 Day 1 Day 2 Day 3 Interday  
 Mean ± SD CV (%) 
Mean 
± SD CV (%) 
Mean 
± SD CV (%) 
Mean 






































































7.3.6 Stability  
 
Short-term stability 
 The unprocessed samples at LQC, MQC, and HQC concentrations of CBD, THC, 
and 11-OH-THC remained stable after 6 hours at room temperature (Table 7.8). One 
LQC replicate of CBC displayed 20% loss after 6 hours. This decrease in concentration 
could have been a pipetting error as the remaining 5 replicates remained within 15% of 
the nominal concentration (1.40 ng/mL). The processed samples at LQC, MQC, and 




Table 7.8. Comparison of CBD, THC, 11-OH-THC, and CBC in LQC, MQC, and HQC samples 
unprocessed and processed for 6 hours at room temperature to samples extracted at 0 hours. 
Unprocessed and processed samples remained stable, staying within 15% the nominal concentration for 
all cannabinoids. 
 Concentration  
at 0 hr 




at 6 hr 




at 6 hr 





1.39 ± 0.07 
(99.29%) 
 
1.45 ± 0.03 
(103.57%) 




50.59 ± 0.55 
(100.60%) 
 
49.70 ± 0.75 
(98.30%) 




99.37 ± 1.14 
(98.19%) 
111.73 ± 1.32 
(110.41%) 





1.46 ± 0.06 
(104.29%) 
 
1.41 ± 0.09 
(100.71%) 




50.60 ± 0.60 
(100.08%) 
 
48.57 ± 0.52 
(96.06%) 




99.21 ± 3.20 
(98.03%) 
109.13 ± 1.42 
(107.84%) 





1.45 ± 0.05 
(103.57%) 
 
1.46 ± 0.07 
(104.29%) 




51.70 ± 0.37 
(102.25%) 
 
49.62 ± 0.96 
(98.14%) 
52.42 ± 1.30 
(103.68%) 
HQC 100.56 ± 3.53 112.58 ± 1.20 101.61 ± 2.33 
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1.39 ± 0.05 
(99.29%) 
 
1.23 ± 0.06 
(87.86%) 




51.45 ± 0.51 
(101.76%) 
 
48.85 ± 0.55 
(96.62%) 




99.85 ± 2.05 
(98.67%) 
110.13 ± 1.25 
(108.82%) 





 Although long-term stability required the assessment of stability up to 12 months, 
only 1, 2, and 3 months had been analyzed due to missed analysis for 6 and 12 months. 
LQC, MQC, and HQC samples remained stable up to at least 3 months, within ±15% of 
the nominal concentration of CBD, THC, 11-OH-THC, and CBC.  Analysis at 6 and 12 
months is currently ongoing. 
 
Freeze thaw stability 
 The first and third set of freeze thaw stability samples at LQC, MQC, and HQC 
levels remained stable after their respective freeze thaw cycles, within ±15% of the 
nominal concentration of CBD, THC, 11-OH-THC, and CBC. All replicates of HQC for 
THC and CBC from the second set of freeze thaw samples displayed concentrations 
15% greater than the nominal HQC concentration (101.2 ng/mL). All CBD and 11-OH-
THC concentrations at the HQC level in the second set of freeze thaw stability remained 
within the acceptable criteria.  
 
Autosampler stability 
 After 24 hours in the autosampler at 4°C, all six replicates at the LLOQ, LQC, 
MQC, and HQC levels following reinjection remained stable and within ±15% of the 
nominal concentrations with the exception of one HQC replicate of CBC. This indicates 
 62 
that samples could be stored in the autosampler for 24 hours during high throughput 
analysis. 
  
7.3.7 Carry Over 
 
 Carryover was not observed for both the quantifier ions of CBD, THC, 11-OH-
THC, and CBC as well as the respective deuterated internal standards, finding no 
detectable peaks in the double blank, following an injection of the ULOQ standard 
(Figure 7.5). This indicated that samples with higher concentrations of the cannabinoids 
would not impact the accurate quantification of subsequently injected samples. LC-
MS/MS method does not require injection of a double blank between each sample. 
 
 
Figure 7.5. Chromatograms comparing the response of CBD, THC, 11-OH-THC, and CBC quantifier ions 
in ULOQ standard (1a) and double blank (1b). Absence in the response of quantifier ions indicate no 
carryover of cannabinoids from the ULOQ. Similarly, the response from ULOQ (2a) and double blank (2b) 



















7.3.8 Matrix Effects 
 
 CBD and THC showed extensive matrix factors of, 50.37% and 42.35%, 
respectively, in human plasma (Table 7.9). CBD and THC exhibited low extraction 
efficiency, with 51.54% in CBD and 37.38% in THC. CBD and THC expressed high 
recovery, ranging from 88.25-102.33% recovery of CBD and THC in the presence of 
matrix effect. The extensive matrix factor indicated ion suppression, likely due to 
incomplete removal of plasma proteins and phospholipids during sample extraction. 
Protein precipitation may not fully precipitate plasma proteins and does not remove 
phospholipids from the matrix. Drying and reconstituting the samples to concentrate the 
analyte would also increase the concentration of other components in the sample.  
 The addition of a deuterated internal standard corrected for the matrix effect 
caused by the endogenous plasma components (Table 7.10). The peak area ratio 
between the analyte and internal standard was displayed in Table 7.10, indicating 
improvements of extraction efficacy and matrix factor with the inclusion of the internal 
standard. The matrix effect did not affect the sensitivity of the method.  
  
Table 7.9. Peak area of pre-spike, post-spike, and pure spike LQC samples used to calculate the extraction efficacy, 
matrix factor, and recovery of CBD and THC undergoing sample extraction in human plasma. 
 Pre-spike 
Peak Area 
(mean ± SD) 
Post-spike 
Peak Area 
(mean ± SD) 
Pure Spike 
Peak Area 






































Table 7.10. Peak area ratio of pre-spike, post-spike and pure spike LQC samples to demonstrate the internal 
















































8 Analysis of CARE-E pediatric patient samples using the 
plasma LC-MS/MS method 
 
 
 The CARE-E study included 7 participants, ages 1-10 years, and were from 
Saskatoon and under the supervision of Dr. Richard Huntsman.2 All participants were 
diagnosed with refractory epileptic encephalopathy. For the CARE-E dose escalation 
study, participants were administered a 1:20 THC:CBD CBM purchased from 
Cannimed. This CBM also contained 4% CBC. 
 
8.1 Dose Escalation Study 
 
Patients who were enrolled into a dose escalation study were administered an 
increasing dose of the CBD rich CBM at their monthly visit. In addition to measuring 
plasma cannabinoid concentrations, the research group also monitored seizure 
frequency, safety and tolerability, and interactions with the patients’ current 
anticonvulsant therapy.  
 The dose escalation study included 7 monthly visits with the pediatrician. At first 
visit, baseline seizure frequency and blood collection were received. Starting at visit 2, 
patients were introduced to the CBM, with increasing doses of 2-3 mg/kg/day, 5-6 
mg/kg/day, 8-9 mg/kg/day, and 10-12 mg/kg/day of CBD at visits 3, 4, and 5, 
respectively. Before the administration of the next dose, blood was collected to quantify 
the minimum plasma cannabinoid concentration at steady state (CSS,min). At visit 6, 
participants were weaned off the CBM and monitored for changes in seizures at visit 7.  
Plasma samples were analyzed using the validated human plasma LC-MS/MS 
method. Samples were quantified within 3 months of collection, to prevent loss from 
stability issues, with the exception of the visit 5 sample of participant A-05, which was 
analyzed 8 months after blood collection.  
Standard curve ion ratios were averaged and used as the reference ion ratio to 
calculate the relative tolerance of experimental samples. Relative tolerance for the 
degree of ion ratios (Table 8.1) were set by the European Commission.153 Ion ratios 
within the relative tolerance range confirms the presence of cannabinoids. Samples with 
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accuracy values outside the relative tolerance range indicate interference of the 
cannabinoids, which could lead to inaccurate interpretations of cannabinoid plasma 
concentrations. The ion ratio accuracy of the experimental samples was calculated 
following Equation 8.1: 
 
																												𝐼𝑜𝑛	𝑟𝑎𝑡𝑖𝑜	𝑏𝑖𝑎𝑠	(%) 	= 	 ;*+	%-,.*!"#$%&:;*+	%-,.*!'"()"*)	,-*.&
;*+	%-,.*!'"()"*)	,-*.&
             Equation 8.1 
 
Table 8.1. Acceptable tolerance criteria for cannabinoids based on the ion ratio relative intensity 
Ion ratio Relative tolerance 
> 0.50 ± 20% 
0.20 - 0.50 ± 25% 
0.10 - 0.20 ± 30% 





 All plasma samples displayed ion ratios within the relative tolerance criteria and 
indicated no endogenous or exogenous interference with CBD, THC, and CBC (Table 
8.2). 11-OH-THC plasma concentrations were not quantifiable and therefore not 
presented in the data below. 
 
Table 8.2. Ion ratio of CARE-E site A participant samples from visits 2-6, with % bias calculated from the 
















































































































































































































































































CBD displayed the highest concentration of the three cannabinoids (Table 8.3). 
Participant A-04 had the highest CBD concentration, with a Css,min of 124.67 ng/mL at 
dose 10-12 mg CBD/kg/day. At visit 5 (10-12 mg CBD/kg/day), CBD Css,min 
concentrations varied between 24.20-124.67 ng/mL. Though commonly used in high 
concentrations to treat pediatric epilepsy, each individual responded to CBD differently. 
Participants A-03, A-06, and A-07 all became seizure free early in the dose escalation 
study, yet their CBD plasma concentrations were in mid-range compared to the other 
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participants.22 Participant A-04 had the highest CBD plasma concentration but had a 
63% seizure reduction frequency.  
Participant A-05 showed a significant decrease in plasma cannabinoid 
concentrations at 10-12 mg CBD/kg/day. This particular sample was analyzed 8 months 
after blood sample collection, which was out of the long-term stability range of 3 
months. Plasma samples were stored in polystyrene tubes after blood collection. 
Cannabinoids show extensive non-specific binding in polymer plastics. The combination 
of cannabinoid long term instability and non-specific binding may have contributed to 
loss of cannabinoids.  
Most participants displayed linear or dose-independent pharmacokinetics, with 
changes in Css,min proportional to the dose (Figure 8.1). However, participant A-04 
expressed potential non-linear pharmacokinetics, evident between visits 4 (8-9 mg 
CBD/kg/day) and visit 5 (10-12 mg CBD/kg/day). Participant A-04 seizure frequency 
reduction increased from ~50% to 75% between visits 4 and 5.  
  
Table 8.3. Minimum CBD plasma concentrations (ng/mL) at steady state of the CARE-E site A 
(Saskatchewan) participants from visit 1-5 during the dose escalation study. 
Participant  
ID 
Dose (mg CBD/kg/day) 
0 2-3 5-6 8-9 10-12 
A-01 N/D1 25.32 48.19 75.95 93.07 
A-02 BLQ2 11.73 22.39 22.21 42.41 
A-03 BLQ 9.80 24.44 79.89 78.53 
A-04 BLQ 11.07 41.52 54.40 124.67 
A-05 BLQ 10.98 19.20 55.17 24.20 
A-06 N/D 19.51 21.76 58.78 73.50 
A-07 BLQ 8.38 14.80 27.67 54.78 
1N/D: Levels analyzed but not detectable 
2BLQ: Levels below limit of quantification 
 
 All participants, except A-01 and A-04 displayed THC Css,min concentrations 
below 4 ng/mL, the threshold set as the minimum level for effect (Table 8.4). Four of the 
participants had no detectable or quantifiable THC Css,min concentrations until visit 3 (5-6 
mg CBD/kg/day). Participant A-07, who became seizure free after visit 3, had no 
detectable THC levels until after visit 5 (10-12 mg CBD/kg/day).22 Possibly due to low 
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amounts of THC present in the CBD rich CBM, THC levels had less variation compared 
to the other two cannabinoids. At visit 5 (10-12 mg CBD/kg/day), THC Css,min 
concentrations ranged from 1.28-4.34 ng/mL. 
 
Table 8.4.  Minimum THC plasma concentrations (ng/mL) at steady state of the CARE-E site A 
(Saskatchewan) participants from visit 1-5 during the dose escalation study. 
Participant  
ID 
Dose (mg CBD/kg/day) 
0 2-3 5-6 8-9 10-12 
A-01 N/D1 1.20 2.09 3.84 4.34 
A-02 BLQ2 0.81 1.27 1.59 2.58 
A-03 BLQ N/D 0.72 2.40 2.67 
A-04 BLQ BLQ 1.46 1.74 4.09 
A-05 N/D N/D 1.43 2.10 1.28 
A-06 N/D 0.49 0.52 3.54 3.06 
A-07 N/D BLQ N/D N/D 1.13 
1N/D: Levels analyzed but not detectable 
2BLQ: Levels below limit of quantification 
 
Two participants who became seizure free, A-06 and A-07, had the highest CBC 
Css,min concentrations (Table 8.5). Participant A-04 had a disproportional increase of 
CBC between visits 4 and 5 (Figure 8.1). CBC Css,min concentrations at visit 5 (10-12 mg 
CBD/kg/day) varied between 4.88-32.35 ng/mL.  
 
Table 8.5. Minimum CBC plasma concentrations (ng/mL) at steady state of the CARE-E site A 
(Saskatchewan) participants from visit 1-5 during the dose escalation study.  
Participant 
ID 
Dose (mg CBD/kg/day) 
0 2-3 5-6 8-9 10-12 
A-01 N/D1 3.50 4.07 6.34 14.30 
A-02 N/D 2.63 3.65 2.95 4.88 
A-03 N/D 2.45 5.12 7.98 10.44 
A-04 N/D 2.09 8.86 11.17 27.30 
A-05 N/D 3.39 6.34 10.38 10.43 
A-06 N/D 9.35 4.91 21.72 28.84 
A-07 N/D 6.04 10.34 21.18 32.35 




Figure 8.1. Minimum plasma concentration of CBD, CBC, and THC at steady state (CSS,min) of the seven 
CARE-E participants during the CARE-E dose escalation study at site A (Saskatchewan). Adapted from 
Huntsman et al. (2019). Dosage Related Efficacy and Tolerability of Cannabidiol in Children with 













































































































































































































Treatment-Resistant Epileptic Encephalopathy: Preliminary Results of the CARE-E Study. Frontiers in 
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9 Determination of the Unbound Fraction of CBD, THC, CBC, 
and 11-OH-THC in Human Plasma  
 
Cannabinoids display high non-specific binding to material found in commonly 
used plasma protein binding devices, such as polystyrene and cellulose membrane 
filters. Non-specific binding would result in the underestimation of the cannabinoid fu(b). A 
3-solvent extraction technique had been developed to determine the plasma protein 
binding of 11-OH-THC, CBD, THC, and CBC while avoiding potential non-specific 
binding. A comparative analysis of the 3-solvent extraction technique, ultrafiltration, and 
Rapid Equilibrium Dialysis (RED) will determine the efficacy of the newly developed 
plasma protein binding assay.   
Ketogenic diets, a conventional treatment for refractory epileptic encephalopathy, 
could alter lipoprotein production. The literature suggested cannabinoids extensively 
were bound to lipoproteins.81 Increase of lipoprotein production may change the 
unbound fraction (fu(b)) of cannabinoids, ultimately changing the therapeutic response of 
cannabinoids. A thorough understanding of the effects of ketogenic diets, a 
conventional treatment for refractory epileptic encephalopathy, on the unbound fraction 
of cannabinoids would ensure appropriate interpretation of total cannabinoid 
concentrations following quantitative analysis with our LC-MS/MS method.  
 





To determine the efficacy of the ultrafiltration technique, 3 total CBD 
concentrations were targeted – 500 ng/mL, 1500 ng/mL, and 3000 ng/mL. 75 μL of 
working standard was added to 1425 μL blank human plasma. 1 mL of spiked human 
plasma was transferred into the ultrafiltration device to determine the unbound 
cannabinoid fractions. 200 μL from the remaining plasma sample was transferred to a 2 
mL Eppendorf Lo-bind microcentrifuge tube and extracted following the sample 
extraction procedure to determine the total CBD concentration. The ultrafiltration sample 
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was centrifuged using the Beckman Coulter centrifuge with the conditions of 1000xg at 
25°C for 3 minutes.  These conditions allowed ~ 5% of the sample volume (50 μL) to be 
filtered through. The 50 μL filtrate was transferred to a new Eppendorf Lo-bind 
microcentrifuge tube and diluted in human plasma to a final volume of 200 μL. Cold 
acetonitrile and internal standard (610 μL), with a concentration of 1.63 ng/mL, was 
added to sample and centrifuged for 10 minutes at 14000 rpm and 4°C. 700 μL of 
supernatant was dried under filtered air at 37°C and reconstituted using 200 μL mobile 
phase.  
Analysis was conducted using the liquid chromatography tandem mass 
spectrometry (LC-MS/MS) method developed and validated in objective 1. The unbound 
fractions of CBD and THC was determined by measuring the concentration of the 




Results show that the unbound cannabinoid fraction was not detected in the 
filtrate, even at high cannabinoid concentrations (Table 9.1). Targeted concentrations 
were calculated to ensure that the unbound cannabinoid concentrations would fall into 
the standard curve. Concentrations measured for the unbound fraction were 
significantly below the LLOQ, confirming high non-specific binding of the highly lipophilic 
cannabinoids to the plastic and membrane filter of the ultrafiltration devices.  
 







Observed Total CBD 
Concentration 
(ng/mL) 
500 ND1 547.85 
1500 ND1 1521.40 
3000 ND1 3141.85 




9.2 3-solvent extraction technique to determine unbound, lipoprotein, 
and remaining bound fraction of cannabinoids  
 
One technique used radiolabeled compounds with the unbound fraction of drug 
being extracted using a 3-step organic solvent extraction.131 This technique was used 
for highly lipophilic compounds with high plasma protein binding characteristics and had 
issues with binding to plastics. Sethi et al. used radiolabeled compounds and measured 
with liquid scintillation.131 However, because the radiolabeled cannabinoids were difficult 
to synthesize, the 3-step organic solvent extraction technique was modified for liquid 
chromatography tandem mass spectrometry analysis, using non-radiolabeled 
cannabinoids (Figure 9.1).   
 
Figure 9.1. General schematic diagram of 3-solvent extraction technique using isooctane, 2-octanol, and 
acetonitrile to determine unbound, lipoprotein bound, and remaining plasma protein bound fractions of 





The proposed 3-step organic solvent technique (Figure 9.1) required spiking 190 μL 
blank pooled human plasma with 10 μL analyte in 2 mL Eppendorf LoBind 
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microcentrifuge tubes. Samples were vortex mixed for 30 seconds. Samples were 
equilibrated on the orbital shaker for 24 hours at 37°C with a speed of 175 rpm. 
Samples were wrapped in foil to avoid photodegradation of cannabinoids. 
610 μL isooctane and internal standard was added to plasma and gently inverted 30 
times to avoid denaturation of plasma proteins. After inverting, samples were 
centrifuged for 5 minutes at 3000 rpm at 4°C for separation of the organic and aqueous 
phases. 500 μL of the isooctane layer was extracted into borosilicate culture tubes. After 
removal of isooctane, 610 μL 2-octanol and internal standard were added to the plasma, 
gently inverted, and centrifuged. 500 μL of the 2-octanol layer was extracted from the 
plasma sample. Due to high viscosity, 2-octanol was difficult to remove from the 
aqueous phase. Samples were placed in dry ice to freeze the plasma layer to obtain the 
2-octanol phase without disrupting the aqueous phase. Following 2-octanol extraction, 
610 μL acetonitrile and internal standard were added to the plasma, vortex mixed, and 
centrifuged at 14000 rpm for 10 minutes at 4°C. 500 μL of the supernatant was 
extracted from the plasma sample. The acetonitrile portion would contain the remaining 
bound cannabinoid fraction. 
Each portion was dried at 37°C using filtered air and reconstituted with 200 μL 




 The 3-solvent extraction technique repeated over 3 days in replicates of 6 at 25, 
50, and 500 ng/mL provided consistent values, determining the reproducibility and 
reliability of the method.  
11-OH-THC, at all three concentrations, displayed approximately 82.7% plasma 
protein binding, 20% bound to lipoproteins (Table 9.2). CBD presented approximately 
82.1% plasma protein binding with 17.9% bound to lipoproteins while THC displayed 
87.0% plasma protein binding, with 16.7% lipoprotein bound. Lastly, CBC displayed 
approximately 93.4% plasma protein binding and 13.3% lipoprotein binding.  
 Free, lipoprotein-bound, and remaining plasma protein bound fractions at 25, 50, 
and 500 ng/mL exhibited consistent values, indicating plasma proteins have not 
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reached saturation of binding sites. The sum of the free cannabinoid, lipoprotein-bound, 
and remaining plasma protein bound concentrations compared closely to the nominal 
concentration of each cannabinoid, indicating high recovery of the cannabinoids during 
the 3-solvent extraction technique. 
The degree of lipophilicity of the cannabinoid correlated to the protein bound 
fraction. 11-OH-THC and CBD, the least lipophilic, displayed approximately 82.7% and 
82.1% plasma protein binding, respectively, while CBC, the most lipophilic, displayed 
approximately 93.4% plasma protein binding (Table 9.3).  
 
Table 9.2. Concentrations of 11-OH-THC, CBD, THC, and CBC in isooctane, 2-octanol, and acetonitrile 

























(mean ± SD; 
ng/mL) 
11-OH-THC 
25 4.3 ± 1.2 (18.4%) 
4.9 ± 0.5 
(20.9%) 
14.2 ± 0.3 
(60.7%) 23.4 ± 0.5 
50 
 
8.0 ± 0.4 
(17.4%) 
 
8.6 ± 0.5 
(18.7%) 
29.4 ± 0.5 
(63.9%) 46.0± 0.4 
500 
 
68.7 ± 5.8 
(16.1%) 
 
86.5 ± 8.8 
(20.3%) 
270.6 ± 12.8  




4.5 ± 0.4 
(17.0%) 
 
5.5 ± 0.5 
(20.8%) 
16.5 ± 0.6 
(62.2%) 26.5 ± 0.5 
50 
 
10.8 ± 0.8 
(20.0%) 
 
8.4 ± 1.1 
(15.6%) 
34.8 ± 1.0 
(64.4%) 54.0 ± 0.8 
500 
 
84.8 ± 10.4 
(16.8%) 
 
87.9 ± 10.1 
(17.4%) 
331.8 ± 17.1 








3.3 ± 0.4 
(12.4%) 
 
5.1 ± 0.5 
(19.2%) 
18.2 ± 0.9 
(68.4%) 26.6 ± 0.6 





Table 9.3. Unbound and bound fractions of 11-OH-THC, CBD, THC, and CBC in human plasma following 
3-solvent extraction technique. Bound fraction includes lipoprotein and remaining plasma protein bound 
cannabinoids.  
Cannabinoid Unbound (%) Bound (%) 
11-OH-THC 17.3 82.7 
CBD 17.9 82.1 
THC 13.0 87.0 




9.3 Rapid equilibrium dialysis (RED) technique for determining the 
unbound cannabinoid fraction  
 
Rapid Equilibrium Dialysis (RED) could determine the unbound and bound 
fractions of cannabinoids without the interference of non-specific binding. Equilibrium 
dialysis consists of two chambers – a sample chamber and assay chamber (Figure 9.2). 
The plasma sample was introduced to the sample chamber. Phosphate buffered saline 




500 67.0 ± 5.4 
(12.5%) 
 
89.0 ± 7.1 
(16.5%) 
382.4 ± 27.5 
(71.0%) 




1.8 ± 0.3  
(6.5%) 
 
4.2 ± 0.4  
(15.3%) 
21.5 ± 1.0 
(78.2%) 27.5 ± 0.8 
50 
 
3.8 ± 0.1 
(7.1%) 
 
6.6 ± 0.7 
(12.3%) 
43.2 ± 1.7 
(80.6%) 53.6 ± 1.2 
500 
 
32.6 ± 1.4 
(6.1%) 
 
67.4 ± 7.3 
(12.5%) 
437.4 ± 26.0 
(81.4%) 537.4 ± 33.9 
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(PBS) solution was added to the assay chamber. A cellulose membrane insert, with a 
8000 molecular weight cut-off, located between the two chambers, selectively allowed 
only the diffusion of unbound fraction. An incubation period of 4 hours was required to 
ensure plasma protein binding reached equilibrium.  
 
Figure 9.2. Diagram displaying the assay and sample chamber of equilibrium dialysis plate (a) and the 
equilibrium of the unbound drug concentration as it selective diffuses through the cellulose membrane 
insert (b). Rapid equilibrium dialysis plate is dependent to size, with a membrane cutoff of 8 kDa, 




Following the 3-solvent extraction technique, 1000, 5000, and 10000 ng/mL 
concentrations of CBD, THC, 11-OH-THC, and CBC were used for RED analysis. 15 μL 
of analytes was added to 285 μL blank pooled human plasma. 200 μL of sample was 
transferred to the sample chamber of the RED plate. 400 μL of PBS was added to the 
assay chamber. Samples equilibrated for 4 hours in an incubated orbital shaker at 37°C 
and 175 rpm.  
After equilibration, 100 μL of plasma and buffer sample were transferred to 2 mL 
Eppendorf Lo-bind microcentrifuge tubes. 100 μL of blank pooled human plasma and 
phosphate buffer saline solution (PBS) were added to the buffer and plasma samples, 
respectively, to provide similar matrices. 610 μL cold acetonitrile and internal standard 
were added for protein precipitation and centrifuged at 14000 rpm, 4°C for 10 minutes. 












air at 37°C for 30 minutes, and reconstituted with 200 μL mobile phase. Samples were 
analyzed using the validated plasma LC-MS/MS method.  
To determine the recovery of cannabinoids in PBS, 10 μL of 1000 ng/mL working 
solution was added to 190 μL of PBS or plasma in replicates of 6. Two types of buffers, 
Hyclone phosphate buffer saline (PBS) and Gibco Dulbecco’s phosphate buffer saline 
(DPBS) were used to determine if different buffer compositions influenced cannabinoid 
recovery. Samples in PBS and plasma were incubated in 2 mL Eppendorf Lo-bind 
microcentrifuge tubes for 0 and 2 hours. 100 μL of sample was transferred to new 
Eppendorf microcentrifuge tubes. 100 μL of plasma or buffer was added to the tubes to 
provide similar matrices. Samples followed the same procedure as the RED technique 





 The rapid equilibrium dialysis technique was not suitable for plasma protein 
binding analysis of cannabinoids. Loss of unbound cannabinoids during the 4-hour 
incubation period resulted in poor recovery (Table 9.4). The total cannabinoid plasma 
concentration closely matched the theoretical final concentration, indicating no non-
specific binding to the plastic and membrane filter of the RED plate for cannabinoids 
found in the plasma compartment.   
 
Table 9.4. Unbound and total concentration of 11-OH-THC, CBD, THC, and CBC in human plasma using 
Rapid Equilibrium Dialysis with 4-hour incubation time (n=3) 
Cannabinoid Theoretical Plasma  
Total Concentration 
(ng/mL) 
RED Buffer Unbound 
Concentration 
(Mean ± SD; ng/mL) 
RED Plasma Total 
Concentration 
(Mean ± SD; ng/mL) 
11-OH-THC 50 
11.2 ± 0.4 
(26.5%) 
42.2 ± 0.7 
CBD 50 
1.3 ± 0.4 
(2.7%) 
48.9 ± 0.3 
THC 50 ND1 46.5 ± 0.3 
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CBC 50 ND 56.3 ± 1.5 
1ND: Not Detected 
  
A comparison test conducted between PBS and plasma determined the recovery 
of cannabinoids in PBS. The procedure followed similar steps to the RED technique, 
with the exception of the samples incubated in Eppendorf Lo-bind microcentrifuge 
tubes. Recovery was calculated by comparing the buffer cannabinoid concentrations to 
plasma cannabinoid concentrations, following Equation 9.1.    
																																				 
																																					𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦	(%) 	= 	 [=-++-".+*.']/-00&*
[=-++-".+*.']$%"!#"
	× 	100%						                Equation 9.1 
 
At 0 hours, both types of buffers presented no loss of cannabinoids, closely 
comparable to the plasma concentrations of CBD and THC (Table 9.5). At 2 hours, 
extensive loss of cannabinoids in both the Hyclone PBS and Gibco DPBS was 
observed, with approximately 65-76% and 79-88% loss in CBD and THC, respectively. 
Additionally, Hyclone PBS had a lower recovery of CBD and THC compared to the 
Gibco DPBS. At 0 and 2 hours, CBD and THC concentrations remained consistent, 
indicating cannabinoids were stable in human plasma at 2 hours.   
   
Table 9.5. Comparison of CBD and THC concentrations in PBS and human plasma incubated at 0 and 2 
hours, in replicates of 6, and determination of recovery, based on the comparison of CBD and THC 




















0 50.6 ± 2.4 92.7 54.7 ± 2.7 96.6 
Gibco 
DPBS 
0 51.4 ± 0.6 94.1 56.6 ± 1.1 99.8 




2 13.0 ± 0.9 23.8 6.9 ± 0.5 12.4 
Gibco 
DPBS 
2 18.7 ± 1.3 34.2 11.8 ± 1.0 21.1 





10  Development of a Dried Blood Spot Assay for the 
Detection of Prenatal Cannabis Exposure in Newborns 
 
With the legalization of recreational Cannabis in October 2018, there is concern of 
increased Cannabis use in pregnant women. Prevalence reports of prenatal Cannabis 
exposure can be obtained through various assessments, such as self-reporting and 
meconium testing. Self-reporting from mothers provides challenges and inconsistencies 
that can lead to inaccurate determination of the prevalence of prenatal Cannabis 
exposure.47 These challenges include under-reporting, stigmatization of Cannabis use, 
risk of legal consequences, and guilt of knowing the risks to their newborn. Meconium, 
the first pass of stool from a newborn, is often used for Cannabis detection.47 However, 
meconium can only detect Cannabis exposure from the third trimester. Meconium is 
also not readily available for screening. Meconium passing can often be delayed if 
newborns experienced distress during labor. Some newborns may pass their meconium 
during labor, which provides difficulty in sample collection. Cannabis detection in 
neonates requires reliable assessment to determine the prevalence of prenatal 
Cannabis exposure. 
Dried blood spot (DBS) sampling is a technique that requires only a small volume 
of blood, which is advantageous over venepuncture blood sampling from pediatric 
participants. The use of DBS samples allows for analysis of neonate samples and ability 
to screen newborns for exposure to Cannabis through their mothers. DBS tests are 
done during newborn screening for inborn errors of metabolism, typically within the first 
24 hours of birth.127 This technique requires spotting blood on a filter paper, allowing it 
to dry before extracting the blood sample from the paper. Sample extraction process 
represents a challenge to DBS assay development to assure sensitive quantification of 
cannabinoids from very small volume blood samples.  
The CRIS research group are currently conducting a study to determine the 
prevalence of prenatal Cannabis exposure pre- and post-legalization of recreational 
Cannabis. To avoid seasonal bias, 500 DBS samples will be randomly collected and 
deidentified from April, May, and June of 2018 (pre-legalization) and 2019 (post-
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legalization) in Saskatchewan, Manitoba, and British Columbia. A LC-MS/MS method is 
required to detect THC-COOH, CBD, and THC in the neonate DBS samples.  
To assess prevalence of prenatal Cannabis exposure, a number of neonate DBS 
samples collected will represent the entire population of the province and subsequently 
analyzed for detection of THC-COOH, CBD, and THC. Prevalence of prenatal Cannabis 
exposure was determined by the following Equation 10.1: 
 
   𝑃𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒	(%) 	= 	/90"$%	*3	?@2	#-041$#	A.,B	'$,$),$'	)-++-".+*.'#
/90"$%	*3	?@2	#-041$#	-+-1CD$'
	× 	100%   Equation 10.1 
 
10.1  Method Development for Quantitative Analysis 
 
THC-COOH, the main cannabinoid of focus for the DBS assay, provided great 
difficulty with stability and accuracy in our plasma LC-MS/MS assay. Due to drying 
samples with filtered air, oxidation of THC-COOH occurred, causing the loss of the 
analyte. A comparison between drying and reconstituting versus no drying resulted in 
the loss of the analyte with drying the sample.  
THC-COOH has a carboxylic acid functional group, which makes it more suitable 
to use negative ion mode for the mass spectrometer. However, the other cannabinoids 
analyzed worked more effectively in the positive ion mode. Experimental polarity 
switching was used to capture all cannabinoids. Sample run started off with negative ion 
mode for 1.8 min then switched to positive ion mode for the remainder of the run. 
However, THC-COOH and CBD had close retention times, making it difficult to create 
an experimental polarity switch.  
Subsequently, a period polarity switch was conducted by switching between 
negative ionization mode and positive ionization mode constantly throughout the run. 
This resulted in the loss of points on the peak, with only 4 points detected for most 
peaks. For a peak to be quantifiable and properly integrated, 12-20 points require 
capturing per peak. With the MRM conditions for THC-COOH set in positive ionization 
mode and the polarity mode constantly switching between positive and negative 
ionization, the mass spectrometer could not capture enough data points for THC-
COOH, which resulted in an unquantifiable peak.   
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The 2-pH rule indicated the pH of the solvent needs to be less than 2 units of the 
pKa of the analyte in order for the analyte to be predominantly in the unionized form. 
The pKa of THC-COOH is 4.69. The pH value of 0.1 mM ammonium of water and 
methanol was around 5. This indicated that the predominant form of THC-COOH was in 
ionized form. Ionized analytes do not interact well with the stationary phase in the 
column, which led to the analyte favoring the mobile phase and resulted in a lower 
retention time.  
Additionally, pH values within the pKa mobile phase was modified by replacing 
the ammonium formate with 0.1% formic acid. This lowered the pH value to 2.3 and 
resulted in the unionized form of THC-COOH as the predominant form. The mobile 
phase modification allowed THC-COOH to interact with the stationary phase of the 
column and created a more stable retention time.  
 
10.1.1  Method 
 
Stock and working standard solution preparation 
 Stock solution of 50000 ng/mL was prepared by adding 100 μL of 1 mg/mL CBD, 
THC, THC-COOH, 11-OH-THC, CBC, and CBN each to 1400 μL LCMS grade 
methanol. Working standards for the standard curve, prepared by parallel dilution, 
ranged from 294.2-50000 ng/mL. The LLOQ working standard was 294.2 ng/mL. The 
LQC, MQC, and HQC standards for all cannabinoids were 500, 5000, and 40000 
ng/mL, respectively. All samples were prepared in amber autosampler vials, wrapped in 
parafilm to avoid evaporation, and stored at -20°C until day of analysis. 
 
Internal standard preparation 
100 μg/mL CBD-d3, THC-d3, 11-OH-THC-d3, THC-COOH-d3, and CBC-d9 
stock solutions were diluted in methanol to prepare a 100 ng/mL working internal 
standard solution in amber autosampler vials, wrapped in parafilm, and stored at -20°C.  
 
Liquid chromatography conditions 
  Method development and validation experiments utilized the Agilent 1290 Infinity 
LC System with a Zorbax Eclipse XDB-C18 Narrow-Bore 2.1 x 75 mm 3.5-micron 
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column and Zorbax Eclipse XDB-C8 Narrow-Bore 2.1 x 12.5 mm 5-micron guard 
column, both controlled at 50°C, with a flow rate of 700 μL/min for 6 minutes. Gradient 
mobile phase comprised of methanol and water containing 0.1% formic acid, with 
gradient conditions listed in Table 10.1. The autosampler temperature was controlled at 
4°C with a sample injection volume of 5 μL.  
 
Table 10.1. Conditions outlining mobile phase gradient for the DBS LC-MS/MS method 
Time (min) Mobile phase A (%) Mobile phase B (%) 
0.0 - 0.5 25 75 
0.5 - 3.0 10 90 
3.0 - 3.1 25 75 
3.1 - 6.0 25 75 
 
 
Mass spectrometry conditions  
The mass spectrometric instrument consisted of a SCIEX QTrap® 6500 triple 
quadrupole mass spectrometer (Washington, DC), equipped with TurboIonSpray® 
electrospray (ESI) interface, set to 5500 V in positive ionization mode. Retention times 
for THC-COOH, CBD, and THC were 1.80 min, 1.87 min, and 2.75 min respectively. 
Multiple reaction monitoring (MRM) conditions and mass spectrometer parameters, 
outlined in Table 10.2 and 10.3, were optimized. 
 
Table 10.2. Multiple Reaction Monitoring (MRM) conditions for the identification of THC-COOH, CBD, and 
THC in dried blood spots (DBS) 




















THC-COOH 1 345.263 299.200 150 101 27 16 
 
THC-COOH 2 345.263 193.100 150 101 35 10 
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THC-COOH 3 345.263 119.000 150 101 35 16 
 
THC-COOH D3 348.153 302.200 150 121 27 16 
 
CBD 1 315.139 193.200 150 61 25 12 
 
CBD 2 315.139 259.200 150 61 19 14 
 
CBD D3 318.165 196.100 150 56 29 12 
 
THC 1 315.130 193.100 150 91 31 12 
 
THC 2 315.130 259.201 150 91 27 14 
 
THC D3 318.155 196.100 150 96 31 10 
 
 
























50 10 5500 600 70 60 10 
 
Sample preparation  
 10 μL of analyte was added to 190 μL blank human whole blood and vortex 
mixed for 10 seconds. For double blank and blank samples, 10 μL of LCMS grade 
methanol was added to 190 μL blank human whole blood. 50 μL of sample was spotted 
onto the Whatman Protein Saver cards and allowed to fully dry at room temperature in 
the absence of light (~3 hours). Cards were then collected into plastic bags with 
desiccant and stored at -20°C until day of analysis.  
 88 
 On the day of analysis, one 6-mm punch was taken from each spot and placed 
into individual 1.5 mL microcentrifuge tubes. 100 μL of LCMS grade water was added to 
the tube and vortex mixed for 1 minute. For protein precipitation, 310 μL of cold 
acetonitrile and internal standard were added to the sample and vortex mixed for an 
additional 30 seconds. For the double blank, 10 μL LCMS grade methanol was added in 
place of the internal standard. Samples were centrifuged at 14000 rpm for 10 minutes at 
4°C. Samples were then filtered using the Agilent Captiva EMR-Lipid plate. Filtrate was 
transferred to amber HPLC vials with inserts.  
 
10.1.2  Results 
 
10.1.2.1 Issues with dried blood spot quantitative analysis 
 
With a nine-point standard curve, one or two standard points would fail, with no 
specific standard point consistently failing. The quantitative method had issues 
regarding the reproducibility of results. One issue with quantitative analysis for dried 
blood spots derived from determining the exact volume in the 6-mm discs. With dried 
blood spots, chromatographic effects, sample heterogeneity, and hematocrit effects 
would affect the accuracy and precision of measuring the cannabinoid 
concentrations.124,125 Chromatographic effects relate to the diffusion of the sample 
throughout the card. The spot would form a gradient, with the area being spotted having 
the greatest concentration of analyte and the outer edge having the least concentration. 
In conjunction to chromatographic effect, sample heterogeneity would cause error to 
quantitative analysis. The analyte in the sample was not homogenously spread, 
therefore making some areas of the spot more concentrated than others. These two 
factors would make it difficult produce consistent, fully saturated discs.   
In the future, it would be difficult to determine the exact concentration of 
cannabinoids in the newborn dried blood spots. When directly dropped onto the card, 
exact volumes of blood in each DBS disc is unknown. Additionally, cannabinoid 
concentrations quantified in the DBS sample cannot determine the time of exposure 
during pregnancy. In conclusion, developing a quantitative method for dried blood spots 
is not necessary for this study. A qualitative method would be a more suitable approach, 
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with the intent to detect for the presence of THC-COOH, CBD, and THC in the neonate 
DBS samples. 
 
10.2  Method Development for Qualitative/Drug Detection Analysis 
 
With all the problems with DBS testing, quantitative analysis was an unsuitable 
approach to determine prevalence of Cannabis exposure in DBS samples. It was also 
not necessary to measure the accurate concentration of the DBS sample. Time and 
duration of prenatal Cannabis exposure were needed to determine the possible effects 
to the fetus. However, since samples analyzed were randomized and deidentified, we 
could not determine these factors.  
For qualitative analysis, a standard curve was not required. Instead, the focus 
would be on development of a limit of detection (LOD), which could not be used for 
quantification. To determine the LOD, the analyte response needs to be three times 
greater than the noise response adjacent to the peak of the analyte.  
 
10.2.1  Method 
 
A final concentration of 1.47 ng/mL was used as the LOD for the dried blood spot 
assay. The LOD working standard (29.42 ng/mL) was prepared following dilution of the 
previous LLOQ (292.40 ng/mL) working standard. Internal working standard (1.67 
μg/mL) was prepared by dilution of 100 μg/mL CBD-d3, THC-d3, and THC-COOH-d3 in 
methanol. 
To prepare the samples, 10 μL of 29.40 ng/mL working standard was added to 
190 μL blank pooled human whole blood. 50 μL of the sample was spotted onto each 
sample disc on the Whatman 903 Protein Saver card. Samples were then dried at room 
temperature for 3 hours in the absence of light and then stored at -20°C in plastic bags 
with desiccant until day of analysis. 
To extract LOD samples from DBS cards, five 6-mm punches (equivalent to one 
full disc on the Whatman card) were collected into a 2 mL Eppendorf Lo-bind 
microcentrifuge tube. 1 mL of LCMS grade methanol and 5 μL of 1.67 μg/mL internal 
standard were added, and vortex mixed for 1 minute. Samples were then centrifuged at 
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1500 x g at 4°C for 5 minutes. 800 μL was transferred to new Eppendorf microcentrifuge 
tubes and subsequently dried using the LabConco SpeedVac for 1 hour. Samples were 
then reconstituted using 100 μL of mobile phase (25% A:75% B) and transferred to 
amber HPLC vials with inserts for LC-MS/MS analysis.  
 
10.2.2  Method Validation 
  
No current standard method validation guideline exists for dried blood spots. A fit 
for purpose method validation protocol had been established for the DBS assay. 
Method validation would follow the Scientific Working Group for Forensic Toxicology 
(SWGTOX) Standard Practices for Method Validation in Forensic Toxicology 
guidelines.154 Based on the SWGTOX method validation guidelines, carryover, 
interference, matrix effect, limit of detection, and stability would provide sufficient 





Carryover analysis must be conducted to determine if a high concentration may 
interfere with the subsequent injection of a low concentration. Carryover could lead to 
inaccurate quantification of samples. To conduct carryover for a qualitative method, a 
high concentration of analyte was injected into the mass spectrometer, followed by an 
injection of a blank sample and a low concentration sample. A sequence of high 
concentrations must be analyzed until presence of carryover. The highest concentration 
with no detectable peak would be considered the acceptable concentration for carryover 
absence.  
 A final concentration of 14.70 ng/mL will be prepared by adding 10 μL of 294.20 
ng/mL standard to 190 μL blank pooled whole blood. A volume of 50 μL is spotted onto 
the Whatman Protein Saver card and allowed to dry for 3 hours. The LOD (final 
concentration of 1.47 ng/mL) is prepared as the low concentration by adding 10 μL of 
29.42 ng/mL standard to 190 μL blank pooled whole blood. A volume of 50 μL is spotted 
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onto the Whatman Protein Saver card, allowed to dry for 3 hours and stored at -20°C in 




Interference would assess for any potential endogenous interferences that may 
be present in the human blood source. Evaluation of any interferences in the matrix 
required 10 different sources of blood. Blank human whole blood sources were obtained 
from volunteers, with ethics approval. A volume of 50 μL of blank individual blood was 
spotted onto the Whatman Protein Saver card, subsequently allowed to dry for three 
hours in the absence of light and stored in plastic bags with desiccant at -20°C until day 
of analysis. Samples were extracted following the extraction procedure.  
 
10.2.2.3 Matrix Effects 
  
Matrix factor analysis will be conducted to evaluate for any occurrence of ion 
suppression or enhancement. A post-column infusion is required to assess for any 
matrix effect. This requires the use of a tee-connection. Two concentrations, the LOD 
and a high concentration, are necessary to assess the matrix factor. To conduct a test, 
the pure standard is directly infused into the mass spectrometer. Baseline of infusion 
should be constant. Next, a blank dried blood spot sample is injected through the UPLC. 
SWGTOX recommends evaluating the 10 different sources of blank human whole 
blood. A matrix factor effect is present if changes in the baseline, increase or decrease 
in total ion intensity, were present.  
 
10.2.2.4 Limit of Detection 
 
 Replicates of 6 LOD samples would be analyzed each day to determine reliability 
of the concentration based on the signal-to-noise ratio. Both MRM transitions of each 
cannabinoid must have a signal-to-noise ratio ³ 3. Additionally, retention time must be 
monitored. The LOD for all cannabinoids used in the assay was 1.47 ng/mL.  
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10.2.3  Detection of cannabinoids in neonate dried blood spot samples in 
Saskatchewan pre-legalization of recreational Cannabis 
 
 Five hundred residual neonate DBS samples from June 2018 were collected 
from the Roy Romanow Provincial Lab in Regina, Saskatchewan. The randomly 
selected DBS cards required fully saturated discs to ensure consistency in each 6-mm 
punch. Each sample consisted of 5 6-mm punches, collected in 2 mL Eppendorf Lo-bind 
microcentrifuge tubes, and stored in a large plastic bag with desiccant in a -20°C freezer 
until day of analysis. 220 samples were extracted following the sample extraction 
procedure and analyzed subsequently after the LOD assessment from the second day 
of method validation.  
 
10.3  Results 
 
 We have developed a sensitive and selective qualitative LC-MS/MS assay for the 
detection of CBD, THC, and THC-COOH in dried blood spots. We obtained a LOD of 
1.47 ng/mL for all three cannabinoids, with signal-to-noise ratios greater than 3.  THC-
COOH, CBD, and THC eluted at retention times of 1.82, 1.89, and 2.82 minutes, 




Figure 10.1. Chromatogram displaying the LOD (1.47 ng/mL) of CBD, THC (a) and THC-COOH (b), 
achieving signal-to-noise (s/n) ratio greater than 3 in positive ionization mode. 
 
10.3.1  Limit of Detection 
 
 Evaluation of LOD depended on detection of signal-to-noise ratios greater than 3. 
Two days of assessment, 6 replicates of LOD concentrations (1.47 ng/mL) each day, 
achieved signal-to-noise ratios greater than 3.  Third day of LOD assessment could not 
be evaluated due to the COVID-19 pandemic. Method validation will continue once 
university laboratories open. 
 
10.3.2  Prenatal Cannabis exposure detection in Saskatchewan June 2018 
neonate DBS samples 
 
 220 neonate DBS samples were analyzed, following the second day of method 
validation. A total of 87 DBS samples displayed peaks for the THC-COOH 1 transition. 
However, only 11 of samples had detectable peaks for THC-COOH 1 (signal-to-noise 
ratio greater than 3), displayed in Table 10.4. Additionally, the same 11 samples 
































Cannabis exposure pre-legalization of recreational Cannabis displayed a prevalence of 
5%. The LC-MS/MS assay determined no CBD or THC detected in all 220 neonate DBS 
samples. Analysis of the remaining 280 samples will be conducted in the future.   
 
Table 10.4. Detection of THC-COOH, CBD, and THC following analysis of 220 Saskatchewan neonate 
DBS samples (June 2018) obtained from the Roy Romanow Provincial Lab 















220 11 0 0 
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11  Discussion 
 
11.1  Context 
 
 Cannabis has recently gained the interest of researchers and pediatricians as a 
potential alternative treatment of refractory epileptic encephalopathy. Yet, lack of 
thorough science-based evidence on the efficacy of Cannabis therapy creates 
uncertainty in the safety of pediatric Cannabis use. Furthermore, no standardized 
dosage regimen exists for the pediatric population. The few clinical studies examining 
Cannabis based medicine (CBM) for pediatric epilepsy have differed in the strain of 
Cannabis plants and administered dose, varying in efficacy and adverse effects.58-64 A 
standardized dosage regimen can ensure Cannabis therapy is safe and effective for 
children with refractory epilepsy.  
 Currently, Cannabis dosage regimens for pediatric use are extrapolated from 
adult dosages, based on body weight.90 A University of Saskatchewan led national open 
label dose-escalation study of CBM use, the CARE-E trial, was designed to help identify 
an appropriate dose of CBM for pediatric refractory encephalopathy by monitoring 
seizure frequency reduction and adverse effects with increasing doses.2 The CARE-E 
study also intended to define the relationship between the bioactive cannabinoid Css,min 
levels and dose, evaluating for linear or nonlinear pharmacokinetics and to provide the 
dose to conduct a single oral pharmacokinetic (PK) study in children. A single oral 
pharmacokinetic study can determine pharmacokinetic parameters, such as Cmax, Tmax, 
ke, t1/2, and AUC, essential for developing a standard dosage regimen. Since it is widely 
known that age-dependent pharmacokinetics exist in the pediatric population, 
characterization of age-dependent pharmacokinetics is required to develop appropriate 
age-stratified dosage regimens, ensuring the child receives optimal therapeutic 
responses to the Cannabis oil therapy while avoiding or minimizing adverse side effects 
associated with Cannabis consumption.94  
 Before conducting a PK study, a highly sensitive bioanalytical method is required 
for accurate measurement and to adequately capture the drug plasma concentration 
versus time profile. Liquid chromatography-tandem mass spectrometry is a bioanalytical 
tool widely used in pharmaceutical and toxicological analysis. Its high sensitivity and 
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selectivity are valuable for the analysis of multiple analytes requiring accurate 
measurements of low concentrations in biological fluids, such as whole blood, plasma, 
urine, and saliva. This is beneficial to capture an appropriate terminal phase in PK 
analysis to define ke, necessary for determining t1/2, as well as residual cannabinoids to 
determine Cannabis exposure.  
 An important factor that may alter pharmacokinetic parameters is diet. CBMs are 
often used as an adjuvant therapy, administered alongside AEDs and ketogenic diets. 
Ketogenic diets, consisting of high fat and low carbohydrates, can increase lipoprotein 
levels in the blood. Cannabinoids appreciably bind to lipoproteins; therefore, increase of 
lipoproteins may ultimately alter the plasma protein binding profile of cannabinoids.80 It 
is imperative to investigate the impact the ketogenic diet will have on the plasma protein 
binding of cannabinoids and determine if dosage adjustments are necessary. Plasma 
protein binding assays are challenged by the extensive non-specific binding of 
cannabinoids to materials conventionally used in plasma protein binding techniques, 
such as ultrafiltration and equilibrium dialysis.82 Adsorption to the surfaces of the 
polymer plastic and membrane filters will result in low recovery of cannabinoids, 
underestimating both the total and unbound cannabinoid concentration.    
 While Cannabis therapy is proposed for treating many pediatric medical 
conditions, children may be unintentionally or accidentally exposed. A major concern is 
the potential adverse effects associated with prenatal Cannabis exposure. More reports 
have emerged of pregnant women using Cannabis to help alleviate pregnancy 
symptoms, such as morning sickness.50 Legalization of recreational Cannabis has 
increased accessibility of Cannabis products, which in turn may have increased 
Cannabis consumption in pregnant women, whether use is intentional or not. 
Cannabinoids can diffuse through the placental-blood barrier and enter the fetal 
systemic circulation, producing effects observed immediately after birth or delayed until 
adolescence/adulthood.47 It is important to understand the prevalence of prenatal 
Cannabis exposure and the effects associated.  
 To investigate the knowledge gaps in pediatric Cannabis research, specifically 
for the age-dependent pharmacokinetics of cannabinoids, I measured Css,min levels of 
11-OH-THC, CBD, THC, and CBC in pediatric patients by developing a quantitative LC-
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MS/MS method with adequate sensitivity and selectivity. A comparative analysis of 
plasma protein binding assays, using the same LC-MS/MS method, also determined 
which technique captured the cannabinoid plasma protein binding profile while avoiding 
non-specific binding and solubility issues. Additionally, in a separate objective, a 
qualitative LC-MS/MS method was developed to determine the prevalence of prenatal 
Cannabis exposure by detecting the presence of cannabinoids in neonate DBS 
samples.   
 
11.2  LC-MS/MS Method Development and Validation  
 
11.2.1  Method Development  
 
LC-MS/MS method development requires identifying appropriate mobile phase 
conditions (i.e. type of solvents, buffers/pH modifiers, gradient vs isocratic flow, mobile 
phase ratios, and flow rate) required for achieving sufficient analyte separation and 
peak shape as well as an appropriate sample clean-up procedure to ensure minimal 
endogenous interference, reduced matrix effect, and increased sensitivity.  
One of the key parameters for method development is determining to use a 
gradient or isocratic elution for the chromatographic separation. Reverse phase liquid 
chromatography consists of a non-polar stationary phase column and polar mobile 
phase. The mobile phase uses a combination of aqueous (mobile phase A) and organic 
(mobile phase B) solvent. The ratio of organic to aqueous solvent will dictate the elution 
of the analyte. Initial method development led to LC-MS/MS conditions that provided an 
isocratic elution with a run time of 5 minutes, held at 90% mobile phase B. 11-OH-THC 
and CBD peaks overlapped at a retention time of 1.64 minutes. Overlapping analyte 
peaks may result in matrix effects that can impact the overall sensitivity of the method. 
To address this issue, LC conditions were modified to a gradient method. Changes to 
mobile phase ratios, starting with 80% mobile phase B for the first 3.5 minutes, 
increasing to 90% B for 6.5 minutes, then returning to 80% B for the last 3.5 minutes. 
Lowering the organic mobile phase during the beginning of the run resulted in the 
separation of 11-OH-THC and CBD. However, the gradient method increased the total 
run time to 13.5 minutes. As seen in Figure 7.1b, CBC, the last eluting cannabinoid, has 
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a retention time of 9.77 minutes. Gradient methods require additional time after the 
elution of the last analyte to ensure return of mobile phase conditions to initial 
conditions, with recommendations of 5 column volumes to re-equilibrate the column for 
the next sample run.  
Another LC parameter that contributes to method development optimization is 
the flow rate. UPLC instrumentation allows for use of increased flow rate, which can aid 
in shorter total run time. This is beneficial for studies that require high throughput 
analysis. Using a flow rate of 700 μL/min instead of 250 μL/min allowed for 1) shorter 
interactions with the stationary phase of the reverse phase column as well as 2) delivery 
of more cannabinoids to the mass spectrometer.  Shorter interaction with the column 
will lead to shorter retention times and ultimately shorter sample run time. Mobile phase 
ratios were modified again, to 77.5% mobile phase B to ensure adequate separation 11-
OH-THC and CBD while shortening the run time to 10 minutes. Reverting back to an 
isocratic method, mobile phase conditions remain constant throughout the sample run 
and do not require any re-equilibration. Delivery of more charged cannabinoid analytes 
to the mass spectrometer will increase the number of ions transported to the detector, 
increasing peak intensity and ultimately sensitivity.  
Although increased flow rate may deliver more analyte to the mass spectrometer, 
more solvent is also introduced to the instrument, potentially leading to insufficient 
desolvation in the ionization chamber. Inadequate evaporation of solvent will decrease 
the ionization efficiency and subsequently the ions that enter to the quadrupoles. 
Optimization of gas and temperature in the source is required to ensure adequate 
evaporation of the solvent. As the final result, an isocratic method with a flow rate of 700 
μL/min and run time of 10 minutes, held at 77.5% mobile phase B, provided great 
separation of 11-OH-THC (1.83 min), CBD (2.19 min), THC (5.55 min), and CBC (8.50 
min). Additionally, the LC-MS/MS parameter optimization resulted in narrower and 
sharper peaks, increasing the peak height of 11-OH-THC, CBD, THC, and CBC, from 
2.6 x 103, 6.9 x 103, 3.8 x 103, and 2.1 x 103 to 1.1 x 104, 2.1 x 104, 9.2 x 103, and 6.2 x 
103, respectively. Increasing peak height is important when establishing sensitive LLOQ 
values.155 
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Another way to increase sensitivity is optimizing sample preparation techniques 
to aid in removing endogenous interferences and increasing analyte concentrations. 
Many sample preparation approaches were used to increase the sensitivity of the LC-
MS/MS method. Sample concentration was achieved by drying off 700 μL supernatant 
following the protein precipitation step and reconstituting with the mobile phase at a 
lower volume of 200 μL. Extraction efficiency is calculated by comparing pre-spike 
samples (samples fortified with analyte prior to extraction) and pure-spike samples 
(samples fortified with analyte after extraction), where post-spike samples represent 
100% recovery of cannabinoids. The increase of cannabinoid concentration will 
increase peak area and height of the cannabinoids, which is beneficial for increasing 
sensitivity. The LLOQ in the initial LC-MS/MS method was 0.98 ng/mL for 11-OH-THC, 
CBD, and THC, and 1.97 ng/mL for CBC. Addition of sample drying and reconstitution 
with a low mobile phase volume to the sample preparation procedure increased 
sensitivity by two-fold, resulting in LLOQ concentrations of 0.49 ng/mL for 11-OH-THC, 
CBD, and THC, and 0.98 ng/mL for CBC.  
An additional peak with the same MRM transition for the quantifier ion of CBD, 
THC, and CBC was present in all samples, eluting at a retention time of 3.05 minutes 
(Figure 7.3). The peak was also found in the double blank and blank samples, indicating 
possible endogenous interference. However, the interference did not show the MRM 
transitions for the qualifier ions. Most importantly, the unknown peak has a different 
retention time than CBD, THC, and CBC, therefore does not affect accurate 
quantification of the cannabinoids. Further analysis using NMR is required to determine 
the compound and ensure no potential interference to future additional cannabinoids.  
 
11.2.2  Method Validation 
 
After development, the method requires validation to ensure accurate 
quantitative data. Method validation, as per the 2018 FDA Bioanalytical Method 
Validation guidelines, requires, linearity, accuracy, precision, carryover, stability, and 
matrix effect testing.151  
Multiple guidelines for method validation, FDA, EMA, and ICH, consistently 
emphasize the importance of conducting system suitability tests but do not provide 
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specific criteria to conduct and measure system suitability.151,157,158 System suitability is 
an essential parameter to determine the reproducibility and performance of the 
instrumentation, ensuring it provides accurate quantification of samples. MDS Pharma 
Services (MDSPS) has conducted several tests to determine the criteria for system 
suitability, resulting in a cut-off of 6% CV.152  
Typically, system suitability is calculated using the peak area ratio between the 
analyte and internal standard. However, internal standard was not added into the 
system suitability method validation samples, resulting in the calculation being based 
solely on the peak area of the analyte. Nevertheless, the system suitability results were 
within the MDSPS CV criteria, ranging from 0.76 to 3.77%, confirming that the LC-MS 
system is providing reproducible data (Table 7.3).   
 Two of the most important criteria for method validation includes testing the 
accuracy and precision of the LC-MS/MS method, ensuring the method produces 
measured concentrations comparable to the theoretical concentrations in a reproducible 
manner. Intra- and inter-day accuracy and precision for all cannabinoids were within the 
FDA criteria, with observed concentrations of LLOQ and all three QCs within ±20% and 
15% of the nominal concentrations, respectively, as displayed in Table 7.4 and 7.5.151 
Greater variation of accuracy and precision was shown with the LLOQ values for all 
cannabinoids, with accuracy values lower than the nominal LLOQ concentration, due to 
greater influence of the baseline in the measurement of LLOQ peak area.  
 Ion ratio, between the quantifier and qualifier ion, is crucial to ensure peak purity 
and monitor for cannabinoid identification, ensuring no false positive detections due to 
interfering compounds with the same MRM transitions. Ion ratios can also indicate 
saturation of the detector, observed with high concentrations. Ion ratio monitoring during 
method validation, produced CV values ranging from 6.31 to 10.94%, with average ion 
ratios of 0.33, 0.60, 0.94, and 0.50 for CBD, THC, 11-OH-THC, and CBC, respectively 
(Table 7.7). Samples used to determine the consistency of ion ratios included the 
standard curve as well as the accuracy and precision QC samples, ranging in 
concentrations from 0.49 to 125 ng/mL. Ion ratios calculated during method validation 
are consistent, regardless of cannabinoid concentration. Ion ratios of clinical samples 
should be compared to the reference ion ratio, averaged from the standard curve.  
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Complete stability assessment is essential prior to conducting pharmacokinetic 
studies to ensure cannabinoid quantification is not compromised by loss of analytes. 
Stability is important to test under different environments and conditions that may cause 
loss of cannabinoids, such as during storage, under various temperatures, and after 
freezing and thawing of sample (i.e., rapid temperature changes).  
Short term stability QC samples, both unprocessed and processed, were within 
15% of the nominal concentration, with the exception of one LQC unprocessed sample. 
This is likely due to pipetting error as the remaining 5 LQC unprocessed samples were 
within the criteria. Short term stability evaluates for loss of cannabinoids due to potential 
situations where samples may be left at room temperature. These situations can include 
improper storage conditions, samples accidentally left at room temperature, and 
malfunction of LC-MS/MS instrumentation during analysis. Results from the short-term 
stability test indicate if any of the situations occurred; the unprocessed and processed 
samples will remain stable for 6 hours at room temperature.   
Autosampler stability examines if cannabinoids are stable under the autosampler 
temperature during data analysis. Observed QC concentrations reanalyzed 24 hours 
after initial analysis, kept in the autosampler at 4°C, remained within 15% of the nominal 
concentrations, indicating cannabinoid stability. This is important with high throughput 
analysis, as samples may require long residence time with the autosampler prior to 
injection and analysis.  
Finally, freeze-thaw stability assesses cannabinoid stability through three cycles 
of freezing and thawing plasma samples. Samples may experience repeated freezing 
and thawing throughout sample collection, storage, and analysis. Cannabinoid samples 
from the first and third freeze thaw cycle remained stable, within 15% of the nominal 
cannabinoid concentration. HQC samples of THC and CBC from the second cycle 
failed, with plasma cannabinoid concentrations exceeding the nominal values, though 
CBD and 11-OH-THC were within the acceptable criteria. This is likely due to pipetting 
error or instability of cannabinoids after the second freeze-thaw cycle. Reanalysis of the 
complete freeze-thaw stability is required to ensure THC and CBC can endure constant 
freezing and thawing.  
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Both CBD and THC displayed 102.33% and 88.25% recovery, respectively. 
Recovery was calculated by comparing pre-spike and post-spike samples. The high 
recovery suggests the sample extraction procedure sufficiently removes the majority of 
endogenous compounds while maintaining integrity of the cannabinoids.    
Matrix effects, calculated by comparing post-spike and neat samples, is 
prominently present in both CBD and THC, expressing 50.37% and 42.35%, 
respectively (Table 7.9). The high matrix effect indicates substantial ion suppression of 
the cannabinoids. Sample extraction consists only of protein precipitation, which is an 
effective process of removing plasma proteins but does not remove phospholipids.  
Drying and reconstituting will increase the cannabinoid concentrations but will also 
increase the concentration of phospholipids. Phospholipids exists with diverse 
characteristics, ranging in polarity and molecular weights, providing difficulty in 
selectively removing the endogenous compounds during chromatographic 
separation.159 
The addition of deuterated internal standards will help to correct for matrix effect, 
as seen in (Table 7.10). However, phospholipid ion suppression will profoundly affect 
sensitivity of the LC-MS/MS assay. To overcome ion suppression and achieve greater 
sensitivity, more extensive sample clean-up is required. Lipid sorbent plates, such as 
Agilent Captiva EMR-Lipid plates, can sufficiently remove both phospholipids and 
plasma proteins.160  
 
11.3  CARE-E Study 
 
 The overall purpose of the CARE-E study was to select an effective dose with 
minimal adverse effects.2 This study was the first open-label pediatric study to measure 
Css,min CBD, THC, and CBC levels in pediatric patients on the CBD rich CBM therapy. 
The CARE-E dose escalation study started with a dose of 2-3 mg CBD/kg/day, 
increasing monthly to a maximum dose of 10-12 mg CBD/kg/day. My responsibility in 
this study was the quantitative analysis of pediatric blood cannabinoid concentrations. 
This study is the first to quantify cannabinoid plasma concentrations in a pediatric 
Cannabis dose escalation study. Measuring plasma cannabinoid concentrations is 
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important to assess its relationship to pharmacological effects and establish 
pharmacokinetic characteristics. Limited information is available on age-dependent 
cannabinoid pharmacokinetics of the pediatric population. It is necessary to determine 
the pharmacokinetic differences throughout childhood for the development of an 
appropriate age-stratified dosage regimen.  
 
11.3.1  Non-specific binding and cannabinoid instability issues 
 
 Before conducting any study, it is important to recognize any potential issues 
related to the physicochemical properties of the cannabinoids and the materials used. 
Tubes used for blood collection and plasma sample storage as well as the duration of 
sample storage were two important challenges associated with patient blood 
cannabinoid analysis. In previous work done in our lab, Barricor tubes were superior to 
other blood collection tubes commonly used for clinical analysis.158 Other blood 
collection tubes displayed lower or higher cannabinoid plasma concentrations compared 
to the control. Many of these tubes contain additives that can interfere with 
quantification of cannabinoids through either ion suppression or enhancement. Barricor 
tubes provided cannabinoid concentrations comparable to the control tube. Additionally, 
prolonged incubation in the blood collection tubes may subject the cannabinoids to non-
specific binding. 
Polymer plastics, such as polystyrene, polypropylene, and polyethylene, are 
highly hydrophobic molecules. Cannabinoids, which are nonpolar and lipophilic, will 
undergo hydrophobic interaction with the polymer molecules, adsorbing to the sides of 
the plastic tubes.161 Adsorption can be reversed by direct addition of a water miscible 
organic solvent to the tube to release adsorbed cannabinoids from the plastic 
surface.162 However, plasma samples may be initially stored in one tube and later 
aliquoted into specific volumes after. Since cannabinoids adsorb to the plastic surface, 
reduced cannabinoid levels are transferred to the new container, resulting in 
underestimated cannabinoid concentrations. To address this issue, plasma samples are 
immediately aliquoted into low binding plastic tubes upon retrieval of the samples. 
Furthermore, experience from my thesis work suggests a standardized guideline should 
exist for all clinical cannabinoid research, comprehensively detailing appropriate 
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materials and procedures used for blood collection, storage, and analysis. This would 
ensure cannabinoids maintain stability and can provide an ability for interlaboratory 
comparisons of clinical cannabinoid concentrations.  
Another issue observed during the CARE-E study was a significant decrease in 
cannabinoid plasma concentrations of the samples reanalyzed 8-10 months after the 
initial analysis, with approximately 30 to 50% decrease for CBD, THC, and CBC. 
Participant A-05 experienced a decrease in cannabinoid plasma concentration at dose 
10-12 mg CBD/kg/day (Figure 8.1). This was due to stability issues as the sample was 
analyzed 8 months after blood collection. Long-term stability assessment during method 
validation only analyzed cannabinoid stability up to 3 months. Instability of cannabinoids 
at 8 months may be due to a combination of long-term storage of degradation and non-
specific binding to polymer plastics.119,163 After blood collection and plasma separation 
in Barricor vacutainers, plasma is transferred to polystyrene culture tubes and stored at 
-80ºC until analysis. 
 
11.3.2  CARE-E sample analysis 
 
 All participants showed a wide variation in plasma concentrations, with CBD 
Css,min levels ranging from 24.20 - 124.67 ng/mL at the 10 - 12 mg CBD/kg/day dose 
(Table 8.3). Variation in the bioavailability of cannabinoids as well as differences in 
systemic clearance likely explains the differences in cannabinoid exposure. 
Cannabinoids are known to exhibit low and variable bioavailability (THC F= 4-12%; CBD 
F= 13-19% in animals), which is likely due to interindividual variability of first pass 
metabolism.164,165 One important source of variability in the pediatric population is stage 
of postnatal development. Age plays an important role in the maturation of metabolic 
enzymes. Participants varied in age, ranging from 1-10 years of age. Participant A-04, 
who is categorized in the 1-3 year age range, displayed the highest Css,min value at the 
10-12 mg CBD/kg/day dose. CYP3A and CYP2C subfamilies reach maturation by age 2 
years, then exceed adult levels until 10 years, and slowly returning to adult levels by 
puberty.90 Due to immature CYP3A and CYP2C enzymes, Participant A-04 likely had 
reduced first pass metabolism, resulting in increased bioavailability and reduced 
 105 
systemic clearance leading to higher plasma cannabinoid concentrations relative to the 
size of dose.   
 The immaturity of CYP3A and 2C enzymes could also explain the non-linear or 
dose-dependent pharmacokinetics displayed in Participant A-04. With lower expression, 
metabolic enzymes become saturated at higher cannabinoid concentrations, resulting in 
higher bioavailability and exposure to cannabinoids. The role of intestinal efflux 
transporters on cannabinoid bioavailability is uncertain, but CBD is not a substrate of 
efflux transporters and, therefore, CBD is more likely undergoing saturation of first pass 
metabolism.74 A detailed single oral dose-escalation pharmacokinetic study with a larger 
sample size can investigate the potential non-linear pharmacokinetics of CBD, THC, 
and CBC. 
 Systemic clearance (Cls) also plays a significant role in steady state plasma 
concentrations. Systemic clearance, which varies throughout child development, is 
influenced by organ blood flow, plasma protein binding, and hepatic enzymatic 
metabolism.166 Those who experience lower hepatic metabolism may have reduced 
hepatic clearance and increased oral bioavailability, ultimately leading to increase 
exposure to CBD, THC, CBC and the metabolites, such as 11-OH-THC, THC-COOH, 6-
OH-CBD and 7-OH-CBD.  
 
11.3.3  Factors affecting pharmacokinetic variability  
 
Variability of bioavailability and systemic clearance may be driven by other 
factors, such as genetic polymorphism in CYP expression, concomitant medications, 
and diet. CYP3A4, CYP2C9, and CYP2C19 are all major metabolic enzymes 
responsible for the metabolism of THC and CBD. All three CYP enzymes are known to 
have high inter-individual variability due to genetic polymorphism. For example, 
CYP2C9 contains three common variants- CYP2C9.1, CYP2C9.2, and CYP2C9.3.167 
30% of Caucasians express the CYP2C9.2 and CYP2C9.3 variants.167 These two 
variants are uncommon in the Asian and African populations. Approximately 95% of 
people from the Asian and African populations express the wild-type variant, CYP2C9.1. 
Variants CYP2C9.2 and CYP2C9.3 have low in vitro THC metabolic activity, whereas 
THC seems to inhibit the CYP2C9.1 variant.168  
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Drug-drug interactions may also occur with concomitant medications. Many of 
the AEDs, such as clobazam, topiramate, valproic acid, and phenytoin are metabolized 
by the same CYP enzymes as phytocannabinoids.169 As a potent inhibitor of CYP2C9, 
CYP2C19, and CYP2D6, CBD may alter the metabolic activity of several AEDs, 
resulting in varying pharmacological response.170 A common drug-drug interaction often 
seen is CBD and clobazam. Clobazam, a substrate to CYP3A4, undergoes 
demethylation to produce active metabolite, N-desmethylclobazam, a CYP2C19 
substrate.171 Co-administration of CBD and clobazam can increase plasma steady state 
concentrations of clobazam and its active metabolite. Dependent on the therapeutic 
window and steady-state plasma concentrations, increased clobazam and N-
desmethylclobazam levels may lead to better therapeutic outcomes or toxicity, making it 
imperative to closely monitor each AED plasma concentration.  
 THC intoxication has been a concern with use of CBM for pediatric patients. As 
reported in the literature, THC intoxication is exhibited at a plasma concentration of 5 
ng/mL.172 None of the participants reached a THC concentration of 5 ng/mL at the 
highest dose. While participants A-01 and A-04 reached THC concentrations close to 5 
ng/mL at the 10-12 mg CBD/kg/day dose, they did not display any form of intoxication 
during the CBD rich CBM therapy. The possible attenuation of THC intoxication may be 
due to CBD acting as a negative allosteric modulator (NAM) of CB1 receptors, 
decreasing the efficacy of THC.173 Orthosteric ligands of CB1 receptors, such as THC, 
are linked to the psychoactive effects of Cannabis. 
During the dose escalation study, three participants, A-03, A-06, and A-07, 
became seizure free. Participants A-06 and A-07 also had the highest CBC plasma 
concentrations. Recently, researchers have discovered potential antiseizure properties 
in CBC.174 The high CBC plasma concentrations in the two participants may be linked to 
the improvements in seizure frequency. All three participants had mid-range Css,min 
levels for CBD. This disparity is possibly due to inter-individual variability of 
pharmacodynamic processes, specifically age-dependent maturation of cannabinoid 
receptors. The endocannabinoid system (ECS) plays an important role in neural 
development. CB1 receptors have been found in the fetus brain at 14 weeks of 
gestation, though the levels are significantly lower compared to adults.175 CB1 receptor 
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expression in the prefrontal cortex peaks around the age of 5 years before slowly 
decreasing into adulthood.176 In other regions of the brain, such as the frontal cortex, 
hippocampus, basal ganglia, and cerebellum, CB1 receptor expression increases from 
the gestational period to adulthood.175,176 Varying receptor expression may influence the 
pharmacodynamic processes of cannabinoids. More research is required to fully 
understand cannabinoid receptor ontogeny during child development, such as receptor 
density and functionality. 
Although the CARE-E study provided valuable findings for CBM and refractory 
epilepsy, the study was limited to the small sample size. It is difficult to conclusively 
determine the age-dependent PK characteristics from 7 participants. Age groups were 
disproportional, with two participants within 1-3 years, four participants within 4-6 years, 
and 1 participant within 7-10 years of age. It is crucial to have an adequate sample size 
as children in different age groups (i.e. infant, toddler, early child, child, and 
adolescence) greatly differ in physical size, body composition (body water and fat 
proportions), and physiological processes (organ maturation).94 Furthermore, children of 
the same age group can produce variable pharmacokinetic responses due to factors 
such as disease progression, genetic polymorphism, and concomitant medications that 
may lead to drug-drug interactions.177 Even amongst the same age group, children can 
develop at different rates. PK studies using larger sample sizes with equal and sufficient 
numbers of participants in each age category is necessary to establish PK parameters 
related to age differences. The single oral dose PK study will contain a sample size of 
n=6/group with 4 groups- infant (<2 - 3 years old), early child (4 - 6 years old), child (7 - 
10 years old), and adolescence (11-18 years old).  
   
11.4  Plasma Protein Binding Assay 
 
 As previously mentioned, diet can impact the pharmacokinetics of cannabinoids. 
Many children with pediatric epilepsy are placed on a ketogenic diet, a diet containing 
high fat content, to help reduce the seizure frequency. The plasma protein binding 
profile of cannabinoids may alter with increased lipoprotein production due to the high 
fat diet.80  
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 The unbound cannabinoid fraction plays a significant role in understanding the 
changes in the pharmacokinetics of cannabinoids with modifications in plasma protein 
levels. Cannabinoids are classified as high extraction ratio drugs.178,179 The unbound 
cannabinoid plasma concentration represents the concentration producing a 
pharmacological effect. Changes in the unbound fraction of high extraction drugs will 
not affect the unbound steady state plasma concentration following oral administrations, 
but total steady state plasma concentrations will change due to changes in oral 
bioavailability.180 Typically, bioanalytical methods quantify for the total plasma 
concentration. Hence, any observed alteration in total steady state plasma 
concentrations with changes in plasma protein binding may compel changes to the 
dosing regimen if it is not understood that unbound steady state concentrations remain 
unchanged.  
 Changes in the unbound fraction will also impact the distributional characteristics 
of the cannabinoids. Since only the unbound concentration can elicit a pharmacological 
effect, changes in the unbound fraction may result in pharmacodynamic changes 
depending upon the relative volume of distribution and the extent in plasma protein 
binding change.75 Such changes in pharmacodynamics may compel a dosing 
adjustment. Therefore, it is important to define the extent of altered lipoprotein levels to 
calculate the unbound plasma concentrations and monitor if dosage adjustments are 
required. Plasma protein binding profiles can be achieved using plasma protein binding 
assays, such as ultrafiltration and equilibrium dialysis.  
Common plasma protein techniques typically are not suitable for plasma protein 
binding analysis of highly lipophilic compounds owing to extensive non-specific binding 
to hydrophobic plastics, membrane filters, and glassware. Ultrafiltration was conducted 
at total CBD concentrations of 500, 1500, and 3000 ng/mL. However, the 
ultracentrifugation filtrate contained no detectable unbound CBD concentration at any of 
the three levels of total concentrations, indicating non-specific binding. As lipophilic 
compounds, CBD likely underwent hydrophobic interaction with the polystyrene sample 
reservoir.161 Additionally, cannabinoids are possibly sticking to the membrane filter, 
preventing any free cannabinoid to pass into the filtrate cup with the ultrafiltrate. This 
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high non-specific binding suggests that ultrafiltration is not a suitable technique for 
cannabinoid or any lipophilic compound plasma protein binding analysis.181  
RED also provided challenges with measuring the unbound cannabinoid 
concentration. THC and CBC unbound concentrations were not detectable with the 
RED technique. However, the observed total concentrations were comparable to the 
theoretical total concentrations for both cannabinoids, indicating no loss of cannabinoids 
due to non-specific binding to the plastic and membrane filters. Additional tests 
determined cannabinoids have low solubility in buffer, with 65.8 - 76.2% and 78.9 - 
87.6% loss of CBD and THC, respectively, after a 2-hour incubation. The loss of 
cannabinoids correlates with the degree of lipophilicity, CBD being less lipophilic 
compared to THC. Cannabinoid concentrations in plasma remained constant after 2 
hours. Buffer is commonly used in research for its biologically relevance in pH (7.4) and 
isotonicity, similar to the human physiological system. Additionally, as cannabinoids are 
highly plasma protein bound, the plasma proteins may protect cannabinoids from 
adsorption to the surfaces of the apparatus and membrane filter. With the absence of 
plasma proteins in buffer, cannabinoids were also subjected to surface adsorption.182 It 
was also determined that increase of salt concentration increased the polarity of the 
PBS solution, resulting in loss of cannabinoids due to insolubility in aqueous solutions, 
as seen when comparing Hyclone PBS to Gibco DPBS.  
 The 3-solvent extraction procedure was selected as an alternative technique for 
plasma protein binding analysis.131 This technique avoids the use of materials 
susceptible to non-specific binding. Sample extraction was conducted in low-binding 
microcentrifuge tubes. The first step of the three-solvent procedure involves the addition 
of isooctane to the plasma sample. Isooctane is a highly nonpolar, water immiscible 
solvent.131 This allows only the free cannabinoids to partition into the nonpolar phase 
without disrupting the plasma protein bound cannabinoids. The second solvent used in 
the procedure is 2-octanol, an alcohol with an 8-carbon tail. 2-Octanol displays 
characteristics of an alcohol and lipid solvent. With thorough mixing, 2-octanol may 
interact with lipoproteins, modifying the fluidity of the hydrophilic layer of the lipoprotein 
and potentially allowing the cannabinoids to release.132 Due to its 8-carbon tail, 2-
octanol provides an environment for the released cannabinoids to partition into the non-
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polar phase. Other plasma proteins would not be affected as they are more polar 
compared to lipoproteins. Acetonitrile is an organic, water miscible solvent commonly 
used for protein precipitation and is added in the third step of the three-solvent 
procedure. Acetonitrile can reduce the hydration layer surrounding plasma proteins, 
which is important for protein folding.133 As the hydration layer is reduced, plasma 
proteins undergo aggregation and subsequent precipitation with each other resulting in 
the release of the cannabinoids.   
 The total observed cannabinoid concentration, calculated by summation of 
cannabinoid concentrations from the three fractions, was comparable to the total 
theoretical cannabinoid concentration for 11-OH-THC, CBD, THC, and CBC. This 
indicates that the 3-solvent extraction technique yields high recovery, with no or minimal 
indications of non-specific binding. This technique also allows the separation of the 
lipoprotein bound cannabinoids from the other plasma protein bound cannabinoids. 
Isolation of lipoprotein bound fraction can determine altered plasma protein binding with 
increased lipoprotein levels due to ketogenic diets.  
 To accurately quantify the cannabinoids, equal internal standard concentrations 
were present in isooctane, 2-octanol, and acetonitrile. This ensures consistent internal 
standard peak area in all three solvents. However, there is concern about the 
deuterated internal standard undergoing plasma protein binding similar to the analyte, 
which would inaccurately calculate the unbound, lipoprotein-bound, and remaining 
plasma protein bound fractions. If that were the case, the internal standard peak area in 
isooctane would be lower compared to the standard curve and accumulate in the 2-
octanol and acetonitrile fractions. However, the internal standard peak area in the 
isooctane layer was consistent with the internal standard peak areas of the standard 
curve. The internal standard peak area in the 2-octanol layer was significantly lower. 
Due to its high viscosity, 2-octanol required longer drying time. It is possible 
cannabinoids in 2-octanol underwent degradation, but the internal standard would have 
corrected for the issue. Additionally, viscosity can affect the ionization efficiency of 
cannabinoids.183 The higher the viscosity, the lower the rate of evaporation. Incomplete 
solvent evaporation can lower ionization efficiency. Nonetheless, the internal standard 
peak area in the acetonitrile layer remained consistent with the internal standard peak 
 111 
area of the standard curve, indicating no shift of plasma protein binding of the internal 
standard from 2-octanol.   
 Based on the 3-solvent extraction technique, the unbound fraction of 11-OH-
THC, CBD, THC, and CBC was 17.3%, 17.9%, 13.0%, and 6.6%, respectively (Table 
9.3). The results follow a trend where increasing lipophilicity is associated with increase 
of plasma protein binding. Lipoprotein bound fractions of 11-OH-THC, CBD, THC, and 
CBC ranged from 12.3 to 20.9% (Table 9.2). Interestingly, 11-OH-THC displayed higher 
lipoprotein bound fractions compared to CBC. It was assumed increase of lipophilicity 
would increase lipoprotein binding; however, the inverse relationship observed indicates 
otherwise. This may be due to the insufficient interaction time between the cannabinoids 
and 2-octanol. The higher lipophilic compounds, such as THC and CBC, may require 
longer interaction times with 2-octanol for the complete extraction of lipoprotein bound 
cannabinoids. Further analysis with multiple different extraction time periods is 
necessary to accurately quantify the lipoprotein bound fraction of cannabinoids. 
 The results obtained from the 3-solvent extraction technique deviates from the 
previous literature, which has reported cannabinoids are 95-99% plasma protein bound, 
or 1-5% unbound.72 The assessment of cannabinoid plasma protein binding was 
conducted in the 1970s and 1980s. Many limitations were discovered in each of the 
studies as followed in Table 11.1.  
   
Table 11.1. Summary of three cannabinoid plasma protein binding assays, detailing the technique used, 
plasma protein bound fraction, and limitations to the study. 
Study Technique Used Plasma Protein 
Bound Cannabinoids  
Limitations 
Klausner et al.129 Zonal  
ultracentrifugation 
62 - 65% lipoprotein 
bound; 35 - 38% 
residue fraction 
(mainly albumin) 
No measurement of 
the unbound fraction; 
assumption of 100% 
plasma protein 
bound. 
Wahlqvist et al.81 Disc electrophoresis/ 
Agar gel 
electrophoresis 
80 - 95% lipoprotein 
bound; no albumin 
bound 
Inadequate 
separation of each 
plasma protein 
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fraction; inability to 
accurately quantify 





Hunt et al.130 Equilibrium dialysis 92 - 99% total 
plasma protein bound 
Use of PBS solution; 
cannabinoids have 




The 3-solvent extraction technique provides advantages over the previous 
cannabinoid plasma protein binding assays. Each fraction is isolated from the other two, 
allowing for distinct separation between the unbound, lipoprotein bound, and remaining 
plasma protein bound cannabinoids. The 3-solvent extraction technique accounts for 
the unbound cannabinoid concentration. None of the three previous studies provided 
information on the unbound THC concentration.  
 In addition, the previous studies provide semi-quantitative analysis, indicating 
cannabinoids are highly plasma protein bound. In fact, Wahlqvist and Klausner agreed 
that THC predominantly binds to lipoproteins.81,129 Based on our results, cannabinoids 
were 12-20% lipoprotein bound. It is possible that more time is necessary to thoroughly 
mix 2-octanol with the plasma sample to allow the solvent to completely interact with the 
lipoproteins. Analysis of multiple time points will determine an optimal mixing period. 
Additional assessment, using other analytes with well-established plasma protein 






11.5  Dried Blood Spot Assay  
 
 With the legalization of recreational Cannabis, there may be an increase in 
prenatal Cannabis exposure. To evaluate the prevalence of prenatal Cannabis 
exposure, neonate dried blood spots were utilized. Neonate DBS samples are readily 
available to retroactively detect prenatal Cannabis exposure. Newborn DBS screening 
is mandatory for all newborns in Canada. Additionally, all provinces in Canada store the 
neonate DBS samples for approximately 10-20 years, becoming readily available to 
retroactively detect for prenatal Cannabis exposure in a large population at random. 
Cannabinoids can be extracted from the DBS samples and analyzed using LC-MS/MS.  
 Quantitative LC-MS/MS analysis was deemed unfit for DBS cannabinoid 
analysis, with the standard curve consistently failing linearity. Major factors affecting the 
accurate quantification of cannabinoids in DBS include hematocrit effect, paper 
chromatographic or "volcano" effect, sample heterogeneity, and unknown blood spot 
volumes.124,125 Hematocrit effect, the main factor responsible for inaccuracy, is based on 
the interindividual variability of red blood cell levels in whole blood. Higher RBC levels 
tend to have high viscosity, which limits the homogeneous spread of blood in the 
delimited blood spot area of the card.124 This can be problematic as all samples will vary 
in hematocrit level and viscosity; therefore, neonate DBS samples may over- or 
underestimate measured blood cannabinoid concentration.  
 As blood is spotted onto the disc, the blood will diffuse in a chromatographic 
manner, with the center being the most concentrated and the outer edges being less 
concentrated.125 This effect will make it difficult to obtain dried blood spot consistency 
when punching spots from DBS sample. Paper chromatographic effect can be avoided 
by extracting the whole DBS sample; however, this can only be done if blood spot 
volumes are constant in all samples. Exact blood spot volumes are required for 
accurate quantification. This may be problematic with neonate DBS collection, as the 
newborn's heel is pricked with a lancet, allowing blood to drop directly onto the card.  
 Lastly, sample heterogeneity plays a significant role in accuracy. Typically, 
samples require thorough mixing to ensure homogeneously distributed analytes. 
However, after drying, analyte remains stationary with randomized distribution. Parts of 
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the blood spot may have higher amounts of cannabinoids than other areas, which can 
produce inaccurate quantification by either overestimating or underestimating of the 
actual concentrations.125  
 Exact quantification of cannabinoids is not necessary for determining prenatal 
Cannabis exposure. Assessment of randomized and deidentified neonate DBS samples 
cannot provide information about the time and duration of prenatal Cannabis exposure, 
making it impossible to define a concentration-effect relationship. A qualitative analysis 
was developed instead to detect for the presence of cannabinoids, specifically THC-
COOH, CBD, and THC, in neonate DBS samples.  
 Initially for qualitative method development, blank human whole blood samples 
were collected anonymously from the Royal University Hospital in Saskatoon, 
Saskatchewan. Upon assessing for interferences/selectivity, which requires analyzing 
10 different sources of matrix, many blank samples tested positive for THC-COOH. As 
recreational Cannabis is now legal and widely used in adults, anonymous whole blood 
samples cannot be used as blank matrices due to potential cannabinoid contamination. 
To overcome this situation, ethics approval was obtained to collect whole blood samples 
from consented participants who do not use Cannabis or have not used within 3 
months. All 10 sources of blank human whole blood did not detect any endogenous 
interferences or cannabinoids.  
 Sample preparation includes methanol extraction, followed by centrifugation, 
drying and reconstituting. A centrifugal concentrator was used instead of a dry bath with 
filtered air to increase sensitivity. With the dry bath, THC-COOH underwent 
degradation, extensively decreasing concentration. Use of the centrifugal concentrator 
maintains stability of THC-COOH while increasing the concentration. 
 For qualitative LC-MS/MS analysis, only a LOD (1.47 ng/mL) is required to detect 
the presence of THC-COOH, CBD, and THC, with the signal-to-noise ratios greater than 
or equal to 3. Three MRM transitions are used to confirm the presence of each 
cannabinoid. To ensure the accuracy of the LOD value, the experiment was conducted 
in two days with 6 replicates, showing that the S/N ratio remained greater than 3. The 
LC-MS/MS qualitative method provided enough sensitivity to detect THC-COOH, CBD, 
and THC in DBS samples, at a concentration of 1.47 ng/mL.  
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 Following LOD determination, we initiated the analysis of neonate DBS samples, 
starting with the analysis of pre-legalization DBS samples from Saskatchewan. Up to 
now, 220 Saskatchewan neonate DBS samples from June 2018 have been analyzed. 
Of the 220 samples, 11 tested positive for THC-COOH, so far indicating a 5% exposure 
rate pre-legalization of recreational Cannabis. This exposure rate is comparable with 
Spain, reporting a prevalence of Cannabis exposure of 5.3%.47  
 CBD and THC were not detected in the samples. Both CBD and THC have 
shorter half-lives than THC-COOH, making them more suitable as drug biomarkers for 
recent drug exposure.23,69 Additionally, CBD and THC stability in DBS samples has not 
been conducted, but CBD and THC in whole blood samples at -80°C have observed 
instability after 52 weeks.119 DBS samples are considered more stable than whole blood 
samples; however, the Saskatchewan samples were stored at 4°C. Therefore, with 
higher storage temperature, it is possible cannabinoids are unstable after 52 weeks. 
Stability assessment is required using the qualitative LC-MS/MS method for 
confirmation.  
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12  Future Work  
 
12.1  LC-MS/MS optimization 
 
 LC-MS/MS assays typically undergo modifications to optimize and improve 
sensitivity and sample run times. More cannabinoids will be added to the assay in the 
future, including 6-OH-CBD, 7-OH-CBD, 7-COOH-CBD, CBN, THCV, CBDV, and CBG. 
The addition of analytes requires sufficient separation; therefore, an isocratic method 
may not be suitable. A gradient method will probably be needed to ensure cannabinoids 
are well separated in a timely manner. 
 The use of the UPLC instrument can further be advantageous with the use of a 
UHPLC column.  These columns contain sub-2-μm particles, which allow for shorter 
sample run times while maintaining peak separation. The columns can also provide 
better peak shapes by increasing peak height and decreasing peak width.184 This would 
be beneficial for THC and CBC as both still display short, wide peaks with the currently 
used LC-MS/MS assay. Shorter sample run times while maintaining adequate 
separation is ideal for high-throughput analysis.  
 Column choice is another potential analytical optimization step. The phenyl-hexyl 
column provides great selectivity to aromatic compounds. This column contains a hexyl 
or 6-carbon alkyl chain and phenyl group attached. The hexyl hydrocarbon chain 
provides greater separation for aromatic analytes. The nonpolar stationary column 
interacts by π-π stacking electron rich bonds between the analyte and stationary phase, 
which will minimize any potential interferences and also reduce background noise, 
leading to greater sensitivity.185,186  
 Removal of phospholipids can minimize matrix effect and ion suppression while 
increasing sensitivity. Agilent Captiva Enhanced Matrix Removal (EMR) Lipid plates 
combines the efficiency of protein precipitation and effectiveness of solid phase 
extraction into one technique.160 This plate uses a proprietary material to selectively 
interact with long chain lipids, trapping them within the filter. Addition of an organic 
solvent, such as acetonitrile, would precipitate plasma proteins. The removal of the two 
major endogenous interferences should provide a much cleaner sample and lower 
 117 
chromatographic baseline. Additionally, the cannabinoids will have less competition for 
ionization, increasing ionization efficiency as phospholipids compete with the analyte for 
charge and surface area on the charged droplet.  
  
12.2  CARE-E Dose Escalation Study 
 
 The CARE-E study is a nationwide study lead by the University of 
Saskatchewan, with study sites at the Universities of British Columbia, Alberta, 
Manitoba, and Montreal. Seven participants from Site A (Saskatchewan) have 
completed the dose escalation study, with more participants recruited and undergoing 
completion of study. Most universities have completed recruitment and the study, with 7 
participants completing the study in British Columbia. We are currently anticipating the 
receival of all patient samples for analysis, necessary for the completion of the CARE-E 
study.  
 
12.3  Pharmacokinetic studies 
 
It is important to understand the physicochemical properties of the analyte(s) 
prior to conducting clinical studies. Potential issues throughout the whole process of the 
clinical study, including blood collection, blood storage, sample preparation, and LC-
MS/MS analysis must be addressed to ensure no potential loss of analyte due to non-
specific binding or unsuitable storage processes.  
Once approved by Health Canada, the CRIS research group will conduct human 
clinical trials, including single oral dose pharmacokinetic studies in children and adults. 
The pediatric PK study will categorize participants into three different experimental 
groups, separated by age- infant (2-3 years old), child (4-6 years old), older child (7-10 
years old), and adolescent (11-18 years old). Conducting the PK study of pediatric 
patients in the diseased state will allow for a better understanding of the 
pharmacokinetics of cannabinoids in patients to identify more optimal dosing 
requirements. Therefore, the PK study will recruit pediatric patients undergoing palliative 
care.  
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The validated human plasma LC-MS/MS assay will be used to quantify the 
cannabinoid plasma concentrations that are necessary for obtaining pharmacokinetic 
parameters, such as Cmax, Tmax, elimination rate constant (k), t1/2, and AUC. These 
parameters are essential to determine age-dependent pharmacokinetic differences of 
cannabinoids, allowing the establishment of suitable dosage regimens in the 
heterogenous pediatric population.  
In conjunction to the age-dependent pediatric pharmacokinetic study, the plasma 
protein binding assay will aid the understanding of the influence of the ketogenic diet on 
the level of lipoproteins. Dietary lipids can increase lipoprotein levels, which may alter 
the plasma protein binding profiles of cannabinoids. The 3-solvent extraction technique 
can determine the possible impact and determine whether or not a dosage adjustment 
is required to ensure adequate therapeutic response to the CBM.  
 
12.4  Dried Blood Spot- Prevalence of Prenatal Cannabis Exposure  
 
The DBS assay will aid in the assessment of the prevalence of prenatal 
Cannabis exposure pre-and post-legalization of recreational Cannabis.  Included in this 
study are British Columbia, Manitoba, and Saskatchewan. The assay will also compare 
differences in prenatal Cannabis exposure in the three provinces. The assay still 
requires completion of method validation, including carry-over, matrix effect, and the last 
day of LOD determination. 
Once method validation is complete 1750 newborn dried blood spot samples will 
be taken from April, May, and June 2018 (pre-legalization) and another 1750 samples 
taken from April, May, and June 2019 (post-legalization) from BC, Manitoba, and 
Saskatchewan. Sample size was calculated to have enough statistical power to 
conclude a 2% change or no change in prevalence. Dates were chosen to avoid bias in 
seasonal changes of Cannabis consumption.  
Many retail stores in Canada could not open immediately following legalization of 
recreational Cannabis or faced shortage issues of Cannabis products. April, May, and 
June 2020 will also be assessed to determine any changes of prenatal Cannabis 
exposure due to greater accessibility of Cannabis products. It is likely that greater 
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accessibility of Cannabis products in 2020 will provide a more accurate evaluation of 
prenatal Cannabis exposure pre- and post-legalization of recreational Cannabis.  
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